这是一篇来自已证抗体库的有关小鼠 表皮生长因子受体 (Egfr) 的综述,是根据278篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合表皮生长因子受体 抗体。
表皮生长因子受体 同义词: 9030024J15Rik; AI552599; Erbb; Errb1; Errp; Wa5; wa-2; wa2

艾博抗(上海)贸易有限公司
domestic rabbit 单克隆(E235)
  • 免疫组化; 大鼠; 图 4h
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab32077)被用于被用于免疫组化在大鼠样本上 (图 4h). Cell Commun Signal (2020) ncbi
小鼠 单克隆(EGFR1)
  • proximity ligation assay; 人类; 图 2a
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab30)被用于被用于proximity ligation assay在人类样本上 (图 2a). Breast Cancer Res (2019) ncbi
domestic rabbit 单克隆(E235)
  • 免疫印迹; 小鼠; 1:2000; 图 3d
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab32077)被用于被用于免疫印迹在小鼠样本上浓度为1:2000 (图 3d). Breast Cancer Res (2019) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 小鼠; 1:1000; 图 3d
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab5652)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 3d). Breast Cancer Res (2019) ncbi
domestic rabbit 单克隆(EP38Y)
  • 免疫组化基因敲除验证; 小鼠; 图 9b
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab52894)被用于被用于免疫组化基因敲除验证在小鼠样本上 (图 9b). Cell Mol Gastroenterol Hepatol (2019) ncbi
domestic rabbit 单克隆(EP38Y)
  • mass cytometry; 人类; 图 3a
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab52894)被用于被用于mass cytometry在人类样本上 (图 3a). Cell (2019) ncbi
domestic rabbit 单克隆(EP38Y)
  • 免疫印迹; 人类; 1:2000; 图 s5
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab52894)被用于被用于免疫印迹在人类样本上浓度为1:2000 (图 s5). J Biol Chem (2019) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 2e
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab5644)被用于被用于免疫印迹在人类样本上 (图 2e). Exp Mol Med (2018) ncbi
domestic rabbit 单克隆(EP38Y)
  • 免疫组化-石蜡切片; 人类; 图 1a
  • 免疫印迹; 人类; 图 1c
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab52894)被用于被用于免疫组化-石蜡切片在人类样本上 (图 1a) 和 被用于免疫印迹在人类样本上 (图 1c). Exp Mol Med (2018) ncbi
domestic rabbit 单克隆(EP38Y)
  • 免疫印迹; 人类; 1:1000; 图 6a
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab52894)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 6a). Cancer Sci (2019) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 5e
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab5644)被用于被用于免疫印迹在人类样本上 (图 5e). Cell Res (2018) ncbi
domestic rabbit 单克隆(EP38Y)
  • 免疫细胞化学; 人类; 1:960; 图 s8
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab52894)被用于被用于免疫细胞化学在人类样本上浓度为1:960 (图 s8). Nat Commun (2017) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:1000; 图 3a
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab5644)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 3a). Nat Commun (2017) ncbi
domestic rabbit 单克隆(EP38Y)
  • 免疫印迹; 人类; 图 2b
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, 1138-1)被用于被用于免疫印迹在人类样本上 (图 2b). Autophagy (2017) ncbi
domestic rabbit 单克隆(EP38Y)
  • 免疫组化-石蜡切片; 人类; 图 4a
  • 免疫印迹; 人类; 图 4d
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab52894)被用于被用于免疫组化-石蜡切片在人类样本上 (图 4a) 和 被用于免疫印迹在人类样本上 (图 4d). Oncol Lett (2016) ncbi
domestic rabbit 单克隆(EP774Y)
  • 免疫印迹; 小鼠; 1:500; 图 1
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, AB40815)被用于被用于免疫印迹在小鼠样本上浓度为1:500 (图 1). J Cell Sci (2016) ncbi
大鼠 单克隆(ICR10)
  • 流式细胞仪; 人类; 1:40; 图 4a
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ICR10)被用于被用于流式细胞仪在人类样本上浓度为1:40 (图 4a). Cancer Res (2017) ncbi
domestic rabbit 单克隆(EP38Y)
  • 免疫印迹; 人类; 1:1000; 图 8
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, EP38Y)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 8). J Cell Sci (2016) ncbi
domestic rabbit 单克隆(EP774Y)
  • 免疫印迹; 人类; 1:800; 图 8
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, EP774Y)被用于被用于免疫印迹在人类样本上浓度为1:800 (图 8). J Cell Sci (2016) ncbi
domestic rabbit 单克隆(EP38Y)
  • 免疫细胞化学; 小鼠; 图 s1
  • 免疫组化; 小鼠; 图 1
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab52894)被用于被用于免疫细胞化学在小鼠样本上 (图 s1) 和 被用于免疫组化在小鼠样本上 (图 1). Nat Commun (2016) ncbi
domestic rabbit 单克隆(EP38Y)
  • 免疫印迹; 人类; 1:1000; 图 7c
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab52894)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 7c). Oncotarget (2016) ncbi
  • 免疫印迹; 小鼠; 图 1B
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab47364)被用于被用于免疫印迹在小鼠样本上 (图 1B). PLoS ONE (2016) ncbi
domestic rabbit 单克隆(EP774Y)
  • 免疫印迹; 人类; 图 4c
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab40815)被用于被用于免疫印迹在人类样本上 (图 4c). Oncotarget (2016) ncbi
domestic rabbit 单克隆(EP38Y)
  • 免疫印迹; 人类; 图 5a
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab52894)被用于被用于免疫印迹在人类样本上 (图 5a). Oncotarget (2016) ncbi
domestic rabbit 单克隆(EP774Y)
  • 免疫印迹; 人类; 图 5a
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab40815)被用于被用于免疫印迹在人类样本上 (图 5a). Oncotarget (2016) ncbi
domestic rabbit 单克隆(EP38Y)
  • 免疫组化-石蜡切片; 人类; 图 3a
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab52894)被用于被用于免疫组化-石蜡切片在人类样本上 (图 3a). Stem Cells Int (2016) ncbi
domestic rabbit 单克隆(E235)
  • 免疫印迹; 人类; 图 5
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab32077)被用于被用于免疫印迹在人类样本上 (图 5). Sci Rep (2015) ncbi
大鼠 单克隆(ICR10)
  • 流式细胞仪; 人类; 表 1
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab231)被用于被用于流式细胞仪在人类样本上 (表 1). PLoS ONE (2015) ncbi
大鼠 单克隆(ICR10)
  • 其他; 小鼠; 1:100; 图 2h
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab231)被用于被用于其他在小鼠样本上浓度为1:100 (图 2h). Cell Death Dis (2015) ncbi
domestic rabbit 单克隆(EP38Y)
  • 免疫印迹; 人类; 图 3
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab52894)被用于被用于免疫印迹在人类样本上 (图 3). Oncotarget (2015) ncbi
domestic rabbit 单克隆(EP774Y)
  • 免疫印迹; 小鼠; 1:1000; 图 5
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(abcam, ab40815)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 5). Mol Cancer (2015) ncbi
domestic rabbit 单克隆(EP38Y)
  • 免疫印迹; 小鼠; 图 s8
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab52894)被用于被用于免疫印迹在小鼠样本上 (图 s8). Sci Rep (2015) ncbi
domestic rabbit 单克隆(EP774Y)
  • 免疫印迹; 小鼠; 图 s8
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab40815)被用于被用于免疫印迹在小鼠样本上 (图 s8). Sci Rep (2015) ncbi
domestic rabbit 单克隆(EP38Y)
  • 免疫细胞化学; 小鼠; 1:100
  • 免疫印迹; 小鼠; 1:1000
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab52894)被用于被用于免疫细胞化学在小鼠样本上浓度为1:100 和 被用于免疫印迹在小鼠样本上浓度为1:1000. Neuroscience (2015) ncbi
domestic rabbit 单克隆(EP774Y)
  • 免疫组化-石蜡切片; 小鼠; 图 6
  • 免疫印迹; 小鼠; 图 s7
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab40815)被用于被用于免疫组化-石蜡切片在小鼠样本上 (图 6) 和 被用于免疫印迹在小鼠样本上 (图 s7). Nat Commun (2015) ncbi
domestic rabbit 单克隆(EP774Y)
  • 免疫印迹; 人类; 图 2
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab40815)被用于被用于免疫印迹在人类样本上 (图 2). Oncotarget (2015) ncbi
domestic rabbit 单克隆(EP38Y)
  • 免疫印迹; 小鼠
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(AbCam, EP38Y)被用于被用于免疫印迹在小鼠样本上. Oncogene (2016) ncbi
domestic rabbit 单克隆(EP774Y)
  • 免疫印迹; 人类; 图  3
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab40815)被用于被用于免疫印迹在人类样本上 (图  3). J Biol Chem (2015) ncbi
小鼠 单克隆(EGFR1)
  • 其他; 小鼠; 图 2,3a,4,5a,5b,6a
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, Ab30)被用于被用于其他在小鼠样本上 (图 2,3a,4,5a,5b,6a). Lasers Surg Med (2015) ncbi
domestic rabbit 单克隆(EP38Y)
  • 免疫组化; 人类
艾博抗(上海)贸易有限公司表皮生长因子受体抗体(Abcam, ab52894)被用于被用于免疫组化在人类样本上. EMBO J (2011) ncbi
圣克鲁斯生物技术
小鼠 单克隆(A-10)
  • 免疫印迹; 人类; 图 10a
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz Biotechnology, sc-373746)被用于被用于免疫印迹在人类样本上 (图 10a). J Virol (2019) ncbi
小鼠 单克隆(A-10)
  • 免疫细胞化学; 人类; 1:150; 图 s4i
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz Biotechnology, sc-373746)被用于被用于免疫细胞化学在人类样本上浓度为1:150 (图 s4i). Science (2018) ncbi
小鼠 单克隆(A-10)
  • 免疫印迹; 人类; 1:660; 图 3a
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz, A-10)被用于被用于免疫印迹在人类样本上浓度为1:660 (图 3a). J Med Chem (2017) ncbi
小鼠 单克隆
  • 免疫印迹; 人类; 1:660; 图 3a
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz, A-10)被用于被用于免疫印迹在人类样本上浓度为1:660 (图 3a). J Med Chem (2017) ncbi
小鼠 单克隆(R-1)
  • 流式细胞仪; 人类; 图 s4b
  • 免疫印迹; 人类; 图 5a
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz, sc-101)被用于被用于流式细胞仪在人类样本上 (图 s4b) 和 被用于免疫印迹在人类样本上 (图 5a). MBio (2017) ncbi
小鼠 单克隆(A-10)
  • 免疫印迹; 大鼠; 图 13a
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz Biotechnology, sc-373746)被用于被用于免疫印迹在大鼠样本上 (图 13a). Am J Pathol (2017) ncbi
小鼠 单克隆(E-8)
  • 免疫印迹; 人类; 1:1000; 图 5d
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz, sc-374607)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5d). Sci Rep (2017) ncbi
小鼠 单克隆(A-10)
  • 免疫印迹; 大鼠; 1:200; 图 5
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz Biotechnology, sc-373746)被用于被用于免疫印迹在大鼠样本上浓度为1:200 (图 5). J Immunol Res (2016) ncbi
小鼠 单克隆(C-2)
  • 免疫印迹; 人类; 图 7c
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz, sc-377229)被用于被用于免疫印迹在人类样本上 (图 7c). EMBO J (2017) ncbi
小鼠 单克隆(R-1)
  • 免疫细胞化学; 人类; 1:250; 图 1a
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz, sc-101)被用于被用于免疫细胞化学在人类样本上浓度为1:250 (图 1a). J Cell Biol (2016) ncbi
小鼠 单克隆(C-2)
  • 免疫印迹; 人类; 1:2000; 图 s6a
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz, sc-377229)被用于被用于免疫印迹在人类样本上浓度为1:2000 (图 s6a). Nat Cell Biol (2016) ncbi
小鼠 单克隆(A-10)
  • 免疫印迹; 人类; 1:1000; 图 4g
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz, SC373746)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 4g). J Biol Chem (2016) ncbi
小鼠 单克隆(528)
  • 流式细胞仪; 中国人仓鼠; 图 1
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz, Sc-120)被用于被用于流式细胞仪在中国人仓鼠样本上 (图 1). Sci Rep (2016) ncbi
小鼠 单克隆(528)
  • 流式细胞仪; 仓鼠; 图 1d
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz, Sc-120)被用于被用于流式细胞仪在仓鼠样本上 (图 1d). Cell Commun Signal (2016) ncbi
小鼠 单克隆(528)
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz Biotechnology, sc-120)被用于. J Cell Sci (2016) ncbi
小鼠 单克隆(528)
  • 免疫细胞化学; 人类; 1:100; 图 7b
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz Biotechnology, sc-120)被用于被用于免疫细胞化学在人类样本上浓度为1:100 (图 7b). Oncotarget (2016) ncbi
小鼠 单克隆(R-1)
圣克鲁斯生物技术表皮生长因子受体抗体(santa Cruz, sc-101)被用于. PLoS Pathog (2016) ncbi
小鼠 单克隆(A-10)
  • 免疫印迹; 人类; 图 4
圣克鲁斯生物技术表皮生长因子受体抗体(santa Cruz, sc-373746)被用于被用于免疫印迹在人类样本上 (图 4). PLoS ONE (2016) ncbi
小鼠 单克隆(R-1)
  • 免疫细胞化学; 人类; 1:100
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz, R-1)被用于被用于免疫细胞化学在人类样本上浓度为1:100. Nature (2016) ncbi
小鼠 单克隆(R-1)
  • 免疫印迹; 人类; 图 1
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz, sc-101)被用于被用于免疫印迹在人类样本上 (图 1). BMC Cell Biol (2015) ncbi
小鼠 单克隆(A-10)
  • 免疫印迹; 人类; 图 6
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz, sc-373746)被用于被用于免疫印迹在人类样本上 (图 6). Cell Death Dis (2015) ncbi
小鼠 单克隆(528)
  • 流式细胞仪; 人类; 1:100; 图 3d
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz, sc-120)被用于被用于流式细胞仪在人类样本上浓度为1:100 (图 3d). Oncotarget (2015) ncbi
小鼠 单克隆(R-1)
  • 免疫细胞化学; 人类; 图 3
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz, sc-101)被用于被用于免疫细胞化学在人类样本上 (图 3). Mol Biol Cell (2015) ncbi
小鼠 单克隆(528)
  • 流式细胞仪; 小鼠; 图 5
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz Biotechnology, SC-120)被用于被用于流式细胞仪在小鼠样本上 (图 5). Analyst (2015) ncbi
小鼠 单克隆(A-10)
  • 免疫印迹; 人类; 图 1
圣克鲁斯生物技术表皮生长因子受体抗体(Santa cruz, sc-373746)被用于被用于免疫印迹在人类样本上 (图 1). PLoS ONE (2015) ncbi
小鼠 单克隆(528)
  • 抑制或激活实验; 人类; 1:200
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz Biotechnology, sc-120)被用于被用于抑制或激活实验在人类样本上浓度为1:200. J Biol Chem (2015) ncbi
小鼠 单克隆(R-1)
  • 免疫沉淀; 人类; 图 5
  • 免疫细胞化学; 人类; 图 s3
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz, sc-101)被用于被用于免疫沉淀在人类样本上 (图 5) 和 被用于免疫细胞化学在人类样本上 (图 s3). J Cell Sci (2015) ncbi
小鼠 单克隆(A-10)
  • 免疫沉淀; 人类
  • 免疫印迹; 人类
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz, sc-373746)被用于被用于免疫沉淀在人类样本上 和 被用于免疫印迹在人类样本上. Am J Pathol (2014) ncbi
小鼠 单克隆(528)
  • 免疫沉淀; 人类
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz, 528)被用于被用于免疫沉淀在人类样本上. Am J Reprod Immunol (2015) ncbi
小鼠 单克隆(528)
  • 免疫印迹; 人类
圣克鲁斯生物技术表皮生长因子受体抗体(Santa Cruz, sc-120)被用于被用于免疫印迹在人类样本上. Mol Oncol (2015) ncbi
小鼠 单克隆(R-1)
  • 免疫组化; 大鼠; 1:200
圣克鲁斯生物技术表皮生长因子受体抗体(Stemcells Inc, SC101)被用于被用于免疫组化在大鼠样本上浓度为1:200. Neuroreport (2014) ncbi
赛默飞世尔
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1 ug/ml; 图 1c
赛默飞世尔表皮生长因子受体抗体(Thermo Fisher, PA1-1110)被用于被用于免疫印迹在人类样本上浓度为1 ug/ml (图 1c). Proc Natl Acad Sci U S A (2019) ncbi
domestic rabbit 多克隆
  • 免疫细胞化学; 人类; 1:250; 图 s4i
赛默飞世尔表皮生长因子受体抗体(ThermoFischer Scientific, 36-9700)被用于被用于免疫细胞化学在人类样本上浓度为1:250 (图 s4i). Science (2018) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:1000; 图 s2a
赛默飞世尔表皮生长因子受体抗体(Thermo Fisher, 36-9700)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 s2a). Nat Med (2017) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 5a
赛默飞世尔表皮生长因子受体抗体(Invitrogen, 44-784G)被用于被用于免疫印迹在人类样本上 (图 5a). Am J Respir Crit Care Med (2017) ncbi
domestic rabbit 多克隆
  • 免疫细胞化学; 人类; 图 1c
赛默飞世尔表皮生长因子受体抗体(Invitrogen, PA1-1110)被用于被用于免疫细胞化学在人类样本上 (图 1c). Oncogene (2017) ncbi
domestic rabbit 多克隆
  • 免疫组化-石蜡切片; 人类; 图 4a
  • 免疫印迹; 人类; 图 4d
赛默飞世尔表皮生长因子受体抗体(Thermo Fisher, 36-9700)被用于被用于免疫组化-石蜡切片在人类样本上 (图 4a) 和 被用于免疫印迹在人类样本上 (图 4d). Oncol Lett (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 5b
赛默飞世尔表皮生长因子受体抗体(Invitrogen, 44-794G)被用于被用于免疫印迹在人类样本上 (图 5b). MAbs (2017) ncbi
小鼠 单克隆(111.6)
  • 免疫组化; 人类; 图 3a
赛默飞世尔表皮生长因子受体抗体(Thermo Scientific, MS-378-PABX)被用于被用于免疫组化在人类样本上 (图 3a). PLoS ONE (2016) ncbi
小鼠 单克隆(H11)
  • 免疫组化; 人类; 1:200; 图 6a
  • 免疫印迹; 人类; 图 1b
赛默飞世尔表皮生长因子受体抗体(Thermo Scientific, H11)被用于被用于免疫组化在人类样本上浓度为1:200 (图 6a) 和 被用于免疫印迹在人类样本上 (图 1b). Oncotarget (2016) ncbi
domestic rabbit 单克隆(EP38Y)
  • 免疫组化-石蜡切片; 人类; 1:30
赛默飞世尔表皮生长因子受体抗体(Thermo Fisher, EP38Y)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:30. Exp Ther Med (2016) ncbi
小鼠 单克隆(111.6)
  • 流式细胞仪; 人类; 图 5
赛默飞世尔表皮生长因子受体抗体(Thermo Scientific, MS-378-PABX)被用于被用于流式细胞仪在人类样本上 (图 5). Sci Rep (2016) ncbi
小鼠 单克隆(111.6)
  • 免疫组化-石蜡切片; 人类; 1:400; 图 1
赛默飞世尔表皮生长因子受体抗体(Lab Vision, 111.6)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:400 (图 1). Biomed Res Int (2015) ncbi
小鼠 单克隆(H11)
  • 免疫细胞化学; 人类; 1:200
赛默飞世尔表皮生长因子受体抗体(NeoMarkers, H11)被用于被用于免疫细胞化学在人类样本上浓度为1:200. Adv Healthc Mater (2015) ncbi
小鼠 单克隆(111.6)
  • 酶联免疫吸附测定; 人类; 图 2
赛默飞世尔表皮生长因子受体抗体(Thermo Scientific, MS-378-PABX)被用于被用于酶联免疫吸附测定在人类样本上 (图 2). Sci Rep (2015) ncbi
小鼠 单克隆(111.6)
  • 免疫印迹; 人类
赛默飞世尔表皮生长因子受体抗体(Thermo Scientific Pierce, MA5-13269)被用于被用于免疫印迹在人类样本上. J Biochem (2015) ncbi
domestic rabbit 单克隆(EP38Y)
  • 免疫组化-石蜡切片; 人类; 1:50; 表 5
赛默飞世尔表皮生长因子受体抗体(Thermo Scientific, EP38Y)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:50 (表 5). PLoS ONE (2014) ncbi
小鼠 单克隆(111.6)
  • 免疫印迹; 人类
赛默飞世尔表皮生长因子受体抗体(Biosource, 111.6)被用于被用于免疫印迹在人类样本上. J Carcinog (2005) ncbi
小鼠 单克隆(H11)
  • 酶联免疫吸附测定; 人类; 表 2
赛默飞世尔表皮生长因子受体抗体(NeoMarkers, MS316-P1ABX)被用于被用于酶联免疫吸附测定在人类样本上 (表 2). Cancer Res (2004) ncbi
小鼠 单克隆(H11)
  • 酶联免疫吸附测定; 人类; 50 ng/well; 表 1
赛默飞世尔表皮生长因子受体抗体(Neomarkers, MS-316-P)被用于被用于酶联免疫吸附测定在人类样本上浓度为50 ng/well (表 1). Cancer Cell (2004) ncbi
小鼠 单克隆(H11)
  • 免疫印迹; 人类; 图 2
赛默飞世尔表皮生长因子受体抗体(NeoMarkers, H-11)被用于被用于免疫印迹在人类样本上 (图 2). Int J Cancer (2004) ncbi
Enzo Life Sciences
小鼠 单克隆(13G8)
  • 免疫印迹; 人类; 图 3a-c
Enzo Life Sciences表皮生长因子受体抗体(Enzo, 13G8)被用于被用于免疫印迹在人类样本上 (图 3a-c). Sci Transl Med (2016) ncbi
小鼠 单克隆(13G8)
  • 免疫印迹; 人类; 图 7a
Enzo Life Sciences表皮生长因子受体抗体(Enzo Life, 13G8)被用于被用于免疫印迹在人类样本上 (图 7a). Nat Commun (2015) ncbi
安迪生物R&D
domestic goat 多克隆
  • 免疫组化; 小鼠; 图 2c
安迪生物R&D表皮生长因子受体抗体(R&D systems, AF1280)被用于被用于免疫组化在小鼠样本上 (图 2c). Circulation (2017) ncbi
西格玛奥德里奇
小鼠 单克隆(29.1)
  • proximity ligation assay; 人类; 图 3c
西格玛奥德里奇表皮生长因子受体抗体(Sigma-Aldrich, E2760)被用于被用于proximity ligation assay在人类样本上 (图 3c). Cancer Res (2017) ncbi
小鼠 单克隆(29.1)
  • 染色质免疫沉淀 ; 人类; 图 5
  • 免疫细胞化学; 人类; 图 1
西格玛奥德里奇表皮生长因子受体抗体(Sigma-Aldrich, E2760)被用于被用于染色质免疫沉淀 在人类样本上 (图 5) 和 被用于免疫细胞化学在人类样本上 (图 1). PLoS ONE (2015) ncbi
赛信通(上海)生物试剂有限公司
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 1:1000; 图 2a: 4c
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(CST, 4267)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 2a: 4c). Nat Commun (2020) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:1000; 图 4c
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(CST, 2234)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 4c). Nat Commun (2020) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫细胞化学; 人类; 1:1000; 图 1c
  • 免疫印迹; 人类; 1:1000; 图 5e
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫细胞化学在人类样本上浓度为1:1000 (图 1c) 和 被用于免疫印迹在人类样本上浓度为1:1000 (图 5e). Cancers (Basel) (2020) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 4a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, D38B1)被用于被用于免疫印迹在人类样本上 (图 4a). Breast Cancer Res (2019) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 1:20,000; 图 2a, 3f, 3k
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上浓度为1:20,000 (图 2a, 3f, 3k). elife (2019) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 1:1000; 图 2a, 3f, 3k
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 2a, 3f, 3k). elife (2019) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 1:1000; 图 e2b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 e2b). Nature (2019) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 1:1000; 图 e2b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 e2b). Nature (2019) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 大鼠; 图 1b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2234)被用于被用于免疫印迹在大鼠样本上 (图 1b). Cell (2019) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 2d
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上 (图 2d). Cell (2019) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 3b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 4267)被用于被用于免疫印迹在人类样本上 (图 3b). Breast Cancer Res (2019) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 2b
  • 免疫印迹; 小鼠; 图 2e
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 4267)被用于被用于免疫印迹在人类样本上 (图 2b) 和 被用于免疫印迹在小鼠样本上 (图 2e). Science (2019) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 1:1000; 图 2f
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777S)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 2f). elife (2019) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 1:1000; 图 2f
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267S)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 2f). elife (2019) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 3b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(cell signaling, 4267)被用于被用于免疫印迹在人类样本上 (图 3b). Sci Rep (2019) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 s2
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2232)被用于被用于免疫印迹在人类样本上 (图 s2). Breast Cancer Res (2019) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 4b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上 (图 4b). J Exp Med (2019) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 1b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267S)被用于被用于免疫印迹在人类样本上 (图 1b). BMC Med Genomics (2019) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 1b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777S)被用于被用于免疫印迹在人类样本上 (图 1b). BMC Med Genomics (2019) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 s6f
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上 (图 s6f). Proc Natl Acad Sci U S A (2019) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 s6f
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2234)被用于被用于免疫印迹在人类样本上 (图 s6f). Proc Natl Acad Sci U S A (2019) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 1c
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2232)被用于被用于免疫印迹在人类样本上 (图 1c). elife (2018) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫细胞化学; 人类; 图 2e
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267S)被用于被用于免疫细胞化学在人类样本上 (图 2e). J Biol Chem (2019) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 小鼠; 图 3g
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在小鼠样本上 (图 3g). Cell (2018) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 1b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 3777)被用于被用于免疫印迹在人类样本上 (图 1b). Proc Natl Acad Sci U S A (2018) ncbi
domestic rabbit 单克隆(53A5)
  • 免疫组化-石蜡切片; 小鼠; 图 s5a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4407)被用于被用于免疫组化-石蜡切片在小鼠样本上 (图 s5a). Mol Cancer Res (2018) ncbi
domestic rabbit 多克隆
  • 其他; 人类; 图 4c
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2232)被用于被用于其他在人类样本上 (图 4c). Cancer Cell (2018) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 1:1000; 图 1e
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 1e). Science (2018) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 小鼠; 1:600; 图 2c
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在小鼠样本上浓度为1:600 (图 2c). Nat Neurosci (2018) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:1000; 图 1a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2232)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 1a). Mol Med Rep (2018) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 1:1000; 图 2e
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 2e). Nat Commun (2017) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 2b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2232)被用于被用于免疫印迹在人类样本上 (图 2b). Cancer Res (2018) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:1000; 图 8c
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 2232)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 8c). Sci Transl Med (2017) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 1:1000; 图 8c
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 3777T)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 8c). Sci Transl Med (2017) ncbi
domestic rabbit 单克隆(C74B9)
  • 免疫印迹; 人类; 图 7f
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(cell signalling, 2646)被用于被用于免疫印迹在人类样本上 (图 7f). Proc Natl Acad Sci U S A (2017) ncbi
domestic rabbit 单克隆(53A5)
  • 免疫印迹; 人类; 图 1a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4407)被用于被用于免疫印迹在人类样本上 (图 1a). Mol Oncol (2017) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 1b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上 (图 1b). Mol Cell Biol (2017) ncbi
domestic rabbit 单克隆(53A5)
  • 免疫印迹; 人类; 图 1b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 53A5)被用于被用于免疫印迹在人类样本上 (图 1b). Cancer Res (2017) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 1b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2232L)被用于被用于免疫印迹在人类样本上 (图 1b). Cancer Res (2017) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 1b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, D7A5)被用于被用于免疫印迹在人类样本上 (图 1b). Cancer Res (2017) ncbi
domestic rabbit 单克隆(53A5)
  • 免疫印迹; 人类; 图 2
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(cell signalling, 4407)被用于被用于免疫印迹在人类样本上 (图 2). Neoplasia (2017) ncbi
domestic rabbit 单克隆(C74B9)
  • 免疫印迹; 小鼠; 图 1f
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2646)被用于被用于免疫印迹在小鼠样本上 (图 1f). Science (2017) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:1000; 图 4g
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2231)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 4g). Physiol Rep (2017) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 小鼠; 图 5a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在小鼠样本上 (图 5a). Sci Rep (2017) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 s3a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上 (图 s3a). Mol Cell (2017) ncbi
domestic rabbit 多克隆
  • reverse phase protein lysate microarray; 人类; 图 st6
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(CST, 2234)被用于被用于reverse phase protein lysate microarray在人类样本上 (图 st6). Cancer Cell (2017) ncbi
domestic rabbit 多克隆
  • reverse phase protein lysate microarray; 人类; 图 st6
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(CST, 2232)被用于被用于reverse phase protein lysate microarray在人类样本上 (图 st6). Cancer Cell (2017) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 2a
  • 免疫印迹; 小鼠; 图 2b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2232S)被用于被用于免疫印迹在人类样本上 (图 2a) 和 被用于免疫印迹在小鼠样本上 (图 2b). Mol Cell Biol (2017) ncbi
domestic rabbit 单克隆(53A5)
  • 免疫印迹; 人类; 图 2a
  • 免疫印迹; 小鼠; 图 2b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4407S)被用于被用于免疫印迹在人类样本上 (图 2a) 和 被用于免疫印迹在小鼠样本上 (图 2b). Mol Cell Biol (2017) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 1f
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell signalling, 4267)被用于被用于免疫印迹在人类样本上 (图 1f). Cancer Lett (2017) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 1f
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell signalling, 3777)被用于被用于免疫印迹在人类样本上 (图 1f). Cancer Lett (2017) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 小鼠; 1:1000; 图 4a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 4a). Theranostics (2017) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫细胞化学; 人类; 1:100; 表 1
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(cell signalling, mAb4267)被用于被用于免疫细胞化学在人类样本上浓度为1:100 (表 1). PLoS ONE (2017) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 小鼠; 1:1000; 图 1g
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 1g). Cell Death Dis (2017) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 5a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上 (图 5a). Am J Respir Crit Care Med (2017) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫组化-石蜡切片; 人类; 1:100
  • 免疫组化; 人类; 图 100
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 4267)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100 和 被用于免疫组化在人类样本上 (图 100). J Toxicol Pathol (2017) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 1:1000; 图 6a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 3777)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 6a). Oncotarget (2017) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 1:1000-1:2000; 图 2a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell signaling, 4267)被用于被用于免疫印迹在人类样本上浓度为1:1000-1:2000 (图 2a). BMC Genomics (2017) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 6a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, D38B1)被用于被用于免疫印迹在人类样本上 (图 6a). Mol Cancer (2017) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 6a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, D7A5)被用于被用于免疫印迹在人类样本上 (图 6a). Mol Cancer (2017) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 4a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在人类样本上 (图 4a). Biomed Pharmacother (2017) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 4a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上 (图 4a). Biomed Pharmacother (2017) ncbi
domestic rabbit 单克隆(53A5)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 4407)被用于被用于免疫印迹在人类样本上. FEBS Open Bio (2017) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 1:1000; 图 1b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 1b). Nat Commun (2017) ncbi
domestic rabbit 多克隆
  • 免疫组化-石蜡切片; 人类; 图 1
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(New England Biolabs, 2234)被用于被用于免疫组化-石蜡切片在人类样本上 (图 1). Oncotarget (2017) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Santa Cruz / Cell Signaling Technology, SC-03 / 2232)被用于被用于免疫印迹在人类样本上. Cell Syst (2017) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 2234)被用于被用于免疫印迹在人类样本上. Cell Syst (2017) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 小鼠; 图 1c
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2231)被用于被用于免疫印迹在小鼠样本上 (图 1c). Exp Clin Endocrinol Diabetes (2017) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 1c
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上 (图 1c). Oncotarget (2017) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 1c
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在人类样本上 (图 1c). Oncotarget (2017) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 6a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell signaling, 3777)被用于被用于免疫印迹在人类样本上 (图 6a). J Cancer (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:1000; 图 3
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2232)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 3). J Cancer Res Clin Oncol (2017) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 小鼠; 图 3
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在小鼠样本上 (图 3). Proc Natl Acad Sci U S A (2016) ncbi
domestic rabbit 单克隆(53A5)
  • 免疫印迹; 小鼠; 图 8b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 53A5)被用于被用于免疫印迹在小鼠样本上 (图 8b). J Biol Chem (2017) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 小鼠; 图 8b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, D38B1)被用于被用于免疫印迹在小鼠样本上 (图 8b). J Biol Chem (2017) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 小鼠; 图 8b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, D7A5)被用于被用于免疫印迹在小鼠样本上 (图 8b). J Biol Chem (2017) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 s3
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上 (图 s3). Neuroendocrinology (2018) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 s3
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在人类样本上 (图 s3). Neuroendocrinology (2018) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 4a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上 (图 4a). Biochem Biophys Res Commun (2017) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 1a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上 (图 1a). Oncotarget (2016) ncbi
domestic rabbit 单克隆(D63B4)
  • 免疫印迹; 人类; 图 3a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, D63B4)被用于被用于免疫印迹在人类样本上 (图 3a). Oncotarget (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 3a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在人类样本上 (图 3a). Oncotarget (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 3b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2234)被用于被用于免疫印迹在人类样本上 (图 3b). Oncotarget (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 2
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上 (图 2). elife (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫细胞化学; 人类; 1:100; 图 s6
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell signaling, 3777S)被用于被用于免疫细胞化学在人类样本上浓度为1:100 (图 s6). Sci Rep (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 7b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上 (图 7b). Cancer Res (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 7b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在人类样本上 (图 7b). Cancer Res (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 中国人仓鼠; 图 2
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在中国人仓鼠样本上 (图 2). Sci Rep (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 1:1000; 图 2
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 2). Sci Rep (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:1000; 图 3C
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2234)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 3C). PLoS ONE (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 4a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在人类样本上 (图 4a). J Exp Clin Cancer Res (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 4c
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上 (图 4c). J Exp Clin Cancer Res (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:1000; 表 s6
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2232)被用于被用于免疫印迹在人类样本上浓度为1:1000 (表 s6). PLoS Genet (2016) ncbi
domestic rabbit 单克隆(C74B9)
  • 免疫印迹; 人类; 1:1000; 图 3f
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2646)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 3f). Exp Ther Med (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫组化; 人类; 1:200; 图 s8c
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫组化在人类样本上浓度为1:200 (图 s8c). Nat Commun (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 1:1000; 图 4a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 4a). Nat Commun (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 1a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在人类样本上 (图 1a). J Biol Chem (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫细胞化学; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, D38B1)被用于被用于免疫细胞化学在人类样本上. Nature (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 1d
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上 (图 1d). Breast Cancer Res (2016) ncbi
domestic rabbit 单克隆(D63B4)
  • 免疫印迹; 人类; 图 2a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 6963)被用于被用于免疫印迹在人类样本上 (图 2a). Breast Cancer Res (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 2f
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 2232)被用于被用于免疫印迹在人类样本上 (图 2f). Biochim Biophys Acta (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:1000; 图 6a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2232)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 6a). Oncotarget (2016) ncbi
domestic rabbit 单克隆(53A5)
  • 免疫印迹; 人类; 1:1000; 图 6a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4407)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 6a). Oncotarget (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 1:1000; 图 5e
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(cell signalling, 4267)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5e). Gut (2017) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 1:1000; 图 5e
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(cell signalling, 3777)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5e). Gut (2017) ncbi
domestic rabbit 单克隆(53A5)
  • 免疫印迹; 人类; 1:1000; 图 s2
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4407)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 s2). Nat Commun (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:1000; 图 s2
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2232)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 s2). Nat Commun (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 1a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在人类样本上 (图 1a). J Proteomics (2017) ncbi
domestic rabbit 单克隆(C74B9)
  • 免疫印迹; 人类; 图 1a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2646)被用于被用于免疫印迹在人类样本上 (图 1a). J Proteomics (2017) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 6
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2234)被用于被用于免疫印迹在人类样本上 (图 6). Sci Rep (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 6
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上 (图 6). PLoS ONE (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:1000; 图 5d
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(cell signalling, 2231)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5d). Oncotarget (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 1:1000; 图 5d
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(cell signalling, 4267)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5d). Oncotarget (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:500; 图 s4
  • 免疫印迹; 小鼠; 1:500; 图 s1
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2234)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 s4) 和 被用于免疫印迹在小鼠样本上浓度为1:500 (图 s1). Nat Commun (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 7e
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell signalling, D38B1)被用于被用于免疫印迹在人类样本上 (图 7e). J Biol Chem (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 7e
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell signalling, D7A5)被用于被用于免疫印迹在人类样本上 (图 7e). J Biol Chem (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 5
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signalling, 2234)被用于被用于免疫印迹在人类样本上 (图 5). Traffic (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 4f
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2232)被用于被用于免疫印迹在人类样本上 (图 4f). Mol Cell (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:500; 图 3
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell signaling, 2234)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 3). Nat Neurosci (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:500; 图 3
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell signaling, 2232)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 3). Nat Neurosci (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:200; 图 2
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell signaling, 2234)被用于被用于免疫印迹在人类样本上浓度为1:200 (图 2). Oncol Lett (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 2220S)被用于被用于免疫印迹在人类样本上. elife (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 3777P)被用于被用于免疫印迹在人类样本上. elife (2016) ncbi
domestic rabbit 单克隆(53A5)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 4407S)被用于被用于免疫印迹在人类样本上. elife (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 2
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 4267)被用于被用于免疫印迹在人类样本上 (图 2). elife (2016) ncbi
domestic rabbit 单克隆(C24A5)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 2641S)被用于被用于免疫印迹在人类样本上. elife (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 4
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(CST, 4267)被用于被用于免疫印迹在人类样本上 (图 4). Oncotarget (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 4
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Tech, 3777)被用于被用于免疫印迹在人类样本上 (图 4). PLoS ONE (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:1000; 图 4b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 2232)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 4b). J Clin Invest (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 1:1000; 图 4b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 3777)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 4b). J Clin Invest (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫组化-石蜡切片; 人类; 图 s1n
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, D38B1)被用于被用于免疫组化-石蜡切片在人类样本上 (图 s1n). Proc Natl Acad Sci U S A (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫组化-石蜡切片; 小鼠; 图 6
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫组化-石蜡切片在小鼠样本上 (图 6). Oncotarget (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫组化-石蜡切片; 小鼠; 图 6
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫组化-石蜡切片在小鼠样本上 (图 6). Oncotarget (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 1
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(CST, 3777s)被用于被用于免疫印迹在人类样本上 (图 1). Oncotarget (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 4
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Tech, 2220)被用于被用于免疫印迹在人类样本上 (图 4). Cancer Sci (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 7
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上 (图 7). Oncotarget (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 4
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell signaling, 2234S)被用于被用于免疫印迹在人类样本上 (图 4). Nat Commun (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 4
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell signaling, 2232S)被用于被用于免疫印迹在人类样本上 (图 4). Nat Commun (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 3d
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3056)被用于被用于免疫印迹在人类样本上 (图 3d). Oncotarget (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫细胞化学; 人类; 图 1b
  • 免疫印迹; 人类; 图 1a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫细胞化学在人类样本上 (图 1b) 和 被用于免疫印迹在人类样本上 (图 1a). Neoplasia (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 3777)被用于被用于免疫印迹在人类样本上. elife (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 8
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 4267)被用于被用于免疫印迹在人类样本上 (图 8). Oncogene (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 8
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 3777)被用于被用于免疫印迹在人类样本上 (图 8). Oncogene (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 1
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 4267)被用于被用于免疫印迹在人类样本上 (图 1). Cell Commun Signal (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 小鼠; 1:1000; 图 3h
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 3h). Nat Commun (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 小鼠; 1:1000; 图 3h
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 3h). Nat Commun (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 4
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 2232)被用于被用于免疫印迹在人类样本上 (图 4). J Cell Sci (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 4
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 2234)被用于被用于免疫印迹在人类样本上 (图 4). J Cell Sci (2016) ncbi
domestic rabbit 多克隆
  • 流式细胞仪; 人类; 2 ug/ml; 图 1
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 2232)被用于被用于流式细胞仪在人类样本上浓度为2 ug/ml (图 1). Cell Death Dis (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 1
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2232)被用于被用于免疫印迹在人类样本上 (图 1). PLoS ONE (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫组化-石蜡切片; 人类; 1:100; 图 s4
  • 免疫印迹; 人类; 1:1000
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 4267)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100 (图 s4) 和 被用于免疫印迹在人类样本上浓度为1:1000. Oncogenesis (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 1:1000; 图 3a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, D38B1)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 3a). J Control Release (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 1:1000; 图 4c
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 4c). Nat Cell Biol (2016) ncbi
domestic rabbit 单克隆(D63B4)
  • 免疫印迹; 人类; 1:1000; 图 s3j
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 6963)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 s3j). Nat Cell Biol (2016) ncbi
domestic rabbit 单克隆(53A5)
  • 免疫印迹; 人类; 1:1000; 图 s3j
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4407)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 s3j). Nat Cell Biol (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫沉淀; 人类; 1:200; 图 2b
  • 免疫印迹; 人类; 1:1000; 图 4a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫沉淀在人类样本上浓度为1:200 (图 2b) 和 被用于免疫印迹在人类样本上浓度为1:1000 (图 4a). Nat Cell Biol (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫细胞化学; 人类; 图 3
  • 免疫印迹; 人类; 图 1
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 4267)被用于被用于免疫细胞化学在人类样本上 (图 3) 和 被用于免疫印迹在人类样本上 (图 1). Proc Natl Acad Sci U S A (2016) ncbi
domestic rabbit 多克隆
  • 免疫细胞化学; 人类; 图 1
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2232)被用于被用于免疫细胞化学在人类样本上 (图 1). Oncotarget (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 1:1000; 图 st12
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signalling, 4267)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 st12). Nat Cell Biol (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 1:1000; 图 st12
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signalling, 3777)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 st12). Nat Cell Biol (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫细胞化学; 人类; 图 1-s1a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell signaling, 4267)被用于被用于免疫细胞化学在人类样本上 (图 1-s1a). elife (2015) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫细胞化学; 人类; 图 1-s1c
  • 免疫印迹; 人类; 图 1-s2c
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell signaling, 3777)被用于被用于免疫细胞化学在人类样本上 (图 1-s1c) 和 被用于免疫印迹在人类样本上 (图 1-s2c). elife (2015) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 3a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell signaling, 2220)被用于被用于免疫印迹在人类样本上 (图 3a). Oncotarget (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 小鼠; 图 2
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Tech, 2234)被用于被用于免疫印迹在小鼠样本上 (图 2). Oncogene (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 6
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在人类样本上 (图 6). PLoS ONE (2015) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 大鼠; 1:1000; 图 3
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777p)被用于被用于免疫印迹在大鼠样本上浓度为1:1000 (图 3). Evid Based Complement Alternat Med (2015) ncbi
domestic rabbit 单克隆(C74B9)
  • 免疫印迹; 小鼠; 图 4
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2646)被用于被用于免疫印迹在小鼠样本上 (图 4). Front Oncol (2015) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 小鼠; 图 4
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在小鼠样本上 (图 4). Front Oncol (2015) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 小鼠; 1:1000; 图 6
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 6). Cell Death Differ (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 小鼠; 1:1000; 图 6
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2238)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 6). Cell Death Differ (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 小鼠; 1:1000; 图 6
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2231)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 6). Cell Death Differ (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 小鼠; 图 6
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 2234s)被用于被用于免疫印迹在小鼠样本上 (图 6). Endocrinology (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 1:2000; 图 s2b
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777S)被用于被用于免疫印迹在人类样本上浓度为1:2000 (图 s2b). Mol Cell (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫沉淀; 人类; 图 1
  • 免疫印迹; 人类; 图 1
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell signaling, D38B1)被用于被用于免疫沉淀在人类样本上 (图 1) 和 被用于免疫印迹在人类样本上 (图 1). Glycobiology (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 1
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell signaling, D7A5)被用于被用于免疫印迹在人类样本上 (图 1). Glycobiology (2016) ncbi
domestic rabbit 单克隆(C74B9)
  • 免疫组化-石蜡切片; 人类; 1:50; 图 4
  • 免疫印迹; 人类; 图 4
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Tech, C74B9)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:50 (图 4) 和 被用于免疫印迹在人类样本上 (图 4). Oncotarget (2015) ncbi
domestic rabbit 单克隆(53A5)
  • 免疫印迹; 人类; 图 3
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4407S)被用于被用于免疫印迹在人类样本上 (图 3). Oncotarget (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 1:2000; 图 3
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上浓度为1:2000 (图 3). PLoS ONE (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫细胞化学; 人类; 图 5
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫细胞化学在人类样本上 (图 5). Oncotarget (2015) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 4
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell signaling, 2231)被用于被用于免疫印迹在人类样本上 (图 4). Oncogene (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 4
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell signaling, 2232)被用于被用于免疫印迹在人类样本上 (图 4). Oncogene (2016) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 1:1000
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 4267)被用于被用于免疫印迹在人类样本上浓度为1:1000. Immunogenetics (2015) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 3777)被用于被用于免疫印迹在人类样本上. Breast Cancer Res (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 4267)被用于被用于免疫印迹在人类样本上. Breast Cancer Res (2015) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 小鼠; 1:500
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在小鼠样本上浓度为1:500. Neuroscience (2015) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 1
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 8543)被用于被用于免疫印迹在人类样本上 (图 1). PLoS ONE (2015) ncbi
domestic rabbit 单克隆(53A5)
  • 免疫印迹; 人类; 图 5
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4407)被用于被用于免疫印迹在人类样本上 (图 5). EBioMedicine (2015) ncbi
domestic rabbit 单克隆(53A5)
  • 免疫印迹; 人类; 图 s3
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4407L)被用于被用于免疫印迹在人类样本上 (图 s3). Oncotarget (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫组化-石蜡切片; 人类; 1:25
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:25. Oncotarget (2015) ncbi
domestic rabbit 单克隆(D63B4)
  • 免疫印迹; 人类; 图 1c,2a,2b,2c,
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(CST, 6963)被用于被用于免疫印迹在人类样本上 (图 1c,2a,2b,2c,). Mol Cancer (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 1:500
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267s)被用于被用于免疫印迹在人类样本上浓度为1:500. Biochim Biophys Acta (2015) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 4
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 3777)被用于被用于免疫印迹在人类样本上 (图 4). Oncotarget (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫组化; 人类; 图 1
  • 免疫印迹; 人类; 图 3
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 4267)被用于被用于免疫组化在人类样本上 (图 1) 和 被用于免疫印迹在人类样本上 (图 3). Oncotarget (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, #4267)被用于被用于免疫印迹在人类样本上. BMC Cancer (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫细胞化学; 人类; 图 3
  • 免疫印迹; 人类; 图 3
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Tech, 4267s)被用于被用于免疫细胞化学在人类样本上 (图 3) 和 被用于免疫印迹在人类样本上 (图 3). Int J Mol Med (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 1:1000; 图 2
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, D38B1)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 2). Nat Commun (2015) ncbi
domestic rabbit 单克隆(D63B4)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 6963)被用于被用于免疫印迹在人类样本上. Mol Cancer Ther (2015) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 3777)被用于被用于免疫印迹在人类样本上. Mol Cancer Ther (2015) ncbi
domestic rabbit 单克隆(D63B4)
  • 免疫印迹; 人类; 图 2a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 6963)被用于被用于免疫印迹在人类样本上 (图 2a). Oncotarget (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 2a, 3b, 4g, 4h
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 4267)被用于被用于免疫印迹在人类样本上 (图 2a, 3b, 4g, 4h). Oncotarget (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 1:1000; 图 s7
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267S)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 s7). Nat Commun (2015) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 1:1000; 图 4
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Tech, 3777)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 4). Oncotarget (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫细胞化学; 人类
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 4267)被用于被用于免疫细胞化学在人类样本上 和 被用于免疫印迹在人类样本上. Int J Oncol (2015) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 3777)被用于被用于免疫印迹在人类样本上. Int J Oncol (2015) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 6
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在人类样本上 (图 6). Cancer Cell (2015) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 小鼠; 1:1000; 图 5a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 5a). Mol Med Rep (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 小鼠; 1:1000; 图 5a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 5a). Mol Med Rep (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technologies, 4267)被用于被用于免疫印迹在人类样本上. J Cell Sci (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上. J Biol Chem (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫细胞化学; 人类
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫细胞化学在人类样本上 和 被用于免疫印迹在人类样本上. J Biol Chem (2015) ncbi
domestic rabbit 单克隆(53A5)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4407)被用于被用于免疫印迹在人类样本上. J Biol Chem (2015) ncbi
domestic rabbit 单克隆(53A5)
  • 免疫印迹; 人类; 图 1a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 53A5)被用于被用于免疫印迹在人类样本上 (图 1a). Oncogene (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 1:1000; 图 2
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, D38B1)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 2). Placenta (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 1
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Signaling Technology, 4267)被用于被用于免疫印迹在人类样本上 (图 1). Oncogene (2015) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫沉淀; 人类
  • 免疫细胞化学; 人类; 1:50
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, D7A5)被用于被用于免疫沉淀在人类样本上, 被用于免疫细胞化学在人类样本上浓度为1:50 和 被用于免疫印迹在人类样本上. Nature (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 小鼠; 1:1000
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在小鼠样本上浓度为1:1000. PLoS ONE (2015) ncbi
domestic rabbit 单克隆(C74B9)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 2646)被用于被用于免疫印迹在人类样本上. J Diabetes (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 2234)被用于被用于免疫印迹在人类样本上. J Diabetes (2016) ncbi
domestic rabbit 单克隆(C74B9)
  • 免疫印迹; 仓鼠; 图 7a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2646)被用于被用于免疫印迹在仓鼠样本上 (图 7a). J Biol Chem (2015) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 大鼠; 1:1000
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 2232S)被用于被用于免疫印迹在大鼠样本上浓度为1:1000. Mol Neurobiol (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 大鼠; 1:1000
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 3777S)被用于被用于免疫印迹在大鼠样本上浓度为1:1000. Mol Neurobiol (2016) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 大鼠; 1:500; 图 10
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在大鼠样本上浓度为1:500 (图 10). J Appl Toxicol (2015) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 图 s1
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在人类样本上 (图 s1). Oncogene (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫细胞化学; African green monkey; 图 6k
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technologies, 4267)被用于被用于免疫细胞化学在African green monkey样本上 (图 6k). Nature (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 5
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, D38B1)被用于被用于免疫印迹在人类样本上 (图 5). Cell Cycle (2014) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫组化-石蜡切片; 人类; 图 1
  • 免疫细胞化学; 人类; 图 1
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫组化-石蜡切片在人类样本上 (图 1) 和 被用于免疫细胞化学在人类样本上 (图 1). Cell Cycle (2014) ncbi
domestic rabbit 单克隆(C74B9)
  • 免疫印迹; 小鼠
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 2646)被用于被用于免疫印迹在小鼠样本上. PLoS ONE (2014) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 小鼠
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777S)被用于被用于免疫印迹在小鼠样本上. PLoS ONE (2014) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类; 图 5
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell signaling, 4267)被用于被用于免疫印迹在人类样本上 (图 5). J Cell Sci (2015) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technologies, 3777)被用于被用于免疫印迹在人类样本上. PLoS ONE (2014) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 1:1000; 图 4B
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 4B). Environ Health Perspect (2015) ncbi
domestic rabbit 单克隆(C74B9)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 2646)被用于被用于免疫印迹在人类样本上. J Cancer Res Clin Oncol (2015) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上. Oncotarget (2014) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 3777)被用于被用于免疫印迹在人类样本上. Biochim Biophys Acta (2014) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 1:1000
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777S)被用于被用于免疫印迹在人类样本上浓度为1:1000. Mol Cancer Ther (2014) ncbi
domestic rabbit 单克隆(C74B9)
  • 免疫印迹; 人类; 图 1c
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 2646)被用于被用于免疫印迹在人类样本上 (图 1c). Mol Cancer Ther (2014) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267S)被用于被用于免疫印迹在人类样本上. J Biol Chem (2014) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫组化-石蜡切片; 人类; 1:400
  • 免疫印迹; 人类; 1:1000
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:400 和 被用于免疫印迹在人类样本上浓度为1:1000. Mol Oncol (2014) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫组化-石蜡切片; 人类; 1:50
  • 免疫印迹; 人类; 1:1000
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, 4267)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:50 和 被用于免疫印迹在人类样本上浓度为1:1000. Mol Oncol (2014) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫组化-自由浮动切片; 鸡
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling Technology, CST-3777)被用于被用于免疫组化-自由浮动切片在鸡样本上. Oncogene (2014) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫印迹在人类样本上. Mol Carcinog (2014) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫印迹在人类样本上. Mol Carcinog (2014) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫组化-石蜡切片; 人类
  • 免疫组化-冰冻切片; 小鼠
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 3777)被用于被用于免疫组化-石蜡切片在人类样本上 和 被用于免疫组化-冰冻切片在小鼠样本上. PLoS ONE (2013) ncbi
domestic rabbit 单克隆(D38B1)
  • 免疫组化-石蜡切片; 人类
  • 免疫组化-冰冻切片; 小鼠
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, 4267)被用于被用于免疫组化-石蜡切片在人类样本上 和 被用于免疫组化-冰冻切片在小鼠样本上. PLoS ONE (2013) ncbi
domestic rabbit 单克隆(D7A5)
  • 免疫印迹; 人类; 1:1000
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell signal, 3777)被用于被用于免疫印迹在人类样本上浓度为1:1000. Cell Tissue Res (2013) ncbi
domestic rabbit 单克隆(C74B9)
  • 免疫细胞化学; 人类; 图 3a
赛信通(上海)生物试剂有限公司表皮生长因子受体抗体(Cell Signaling, C74B9)被用于被用于免疫细胞化学在人类样本上 (图 3a). Sci Signal (2012) ncbi
Fitzgerald Industries
  • 免疫印迹; 小鼠; 图 8a
Fitzgerald Industries表皮生长因子受体抗体(Fitzgerald, 20R-ER004)被用于被用于免疫印迹在小鼠样本上 (图 8a). Autophagy (2015) ncbi
默克密理博中国
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 s4e, s4f
默克密理博中国表皮生长因子受体抗体(Millipore, 06-847)被用于被用于免疫印迹在人类样本上 (图 s4e, s4f). Cell (2019) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:1000; 图 2f
默克密理博中国表皮生长因子受体抗体(Millipore, 06-847)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 2f). Nat Commun (2019) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 5e
默克密理博中国表皮生长因子受体抗体(Millipore, 06-847)被用于被用于免疫印迹在人类样本上 (图 5e). Cell Res (2018) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:1000; 图 s1b
默克密理博中国表皮生长因子受体抗体(Millipore, 06-847)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 s1b). Nat Med (2017) ncbi
小鼠 单克隆(8G6.2)
  • 免疫细胞化学; 人类; 1:500; 图 2d
默克密理博中国表皮生长因子受体抗体(Millipore, 05-1047)被用于被用于免疫细胞化学在人类样本上浓度为1:500 (图 2d). Nat Commun (2017) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 小鼠; 图 5a
默克密理博中国表皮生长因子受体抗体(Millipore, 06-847)被用于被用于免疫印迹在小鼠样本上 (图 5a). Stem Cell Reports (2017) ncbi
小鼠 单克隆(20G3)
  • 其他; 人类; 1:50; 图 1
  • 免疫印迹; 人类; 1:2000; 图 s1
默克密理博中国表皮生长因子受体抗体(Merck Millipore, 05-484)被用于被用于其他在人类样本上浓度为1:50 (图 1) 和 被用于免疫印迹在人类样本上浓度为1:2000 (图 s1). BMC Cancer (2016) ncbi
小鼠 单克隆
  • 免疫细胞化学; 小鼠; 1:750; 图 4
默克密理博中国表皮生长因子受体抗体(Millipore, GR01)被用于被用于免疫细胞化学在小鼠样本上浓度为1:750 (图 4). MAbs (2016) ncbi
domestic rabbit 多克隆
  • 免疫沉淀; 小鼠; 图 2
  • 免疫印迹; 小鼠; 图 1
  • 免疫印迹; 人类; 图 s3
默克密理博中国表皮生长因子受体抗体(Millipore, 06-847)被用于被用于免疫沉淀在小鼠样本上 (图 2), 被用于免疫印迹在小鼠样本上 (图 1) 和 被用于免疫印迹在人类样本上 (图 s3). Nat Commun (2016) ncbi
小鼠 单克隆
  • 免疫细胞化学; 人类; 图 1d
默克密理博中国表皮生长因子受体抗体(Calbiochem, GR01)被用于被用于免疫细胞化学在人类样本上 (图 1d). Nat Struct Mol Biol (2016) ncbi
小鼠 单克隆
  • 免疫细胞化学; 人类; 图 1d
默克密理博中国表皮生长因子受体抗体(Calbiochem, GR01)被用于被用于免疫细胞化学在人类样本上 (图 1d). Nat Struct Mol Biol (2016) ncbi
小鼠 单克隆(13G8)
  • 免疫印迹; 小鼠; 1:300; 图 s4
默克密理博中国表皮生长因子受体抗体(Millipore, 04-290)被用于被用于免疫印迹在小鼠样本上浓度为1:300 (图 s4). Dev Cell (2016) ncbi
domestic rabbit 多克隆
  • 免疫细胞化学; 人类; 1:500; 图 3
  • 免疫印迹; 人类; 1:1000; 图 3
默克密理博中国表皮生长因子受体抗体(Millipore, 06-847)被用于被用于免疫细胞化学在人类样本上浓度为1:500 (图 3) 和 被用于免疫印迹在人类样本上浓度为1:1000 (图 3). elife (2016) ncbi
小鼠 单克隆(13G8)
  • 免疫组化; 小鼠; 1:100; 图 s11
  • 免疫组化; 人类; 1:100; 图 1
默克密理博中国表皮生长因子受体抗体(Millipore, 04-290)被用于被用于免疫组化在小鼠样本上浓度为1:100 (图 s11) 和 被用于免疫组化在人类样本上浓度为1:100 (图 1). Nat Neurosci (2016) ncbi
小鼠 单克隆(20G3)
  • 免疫印迹; 人类; 1:1000
  • 免疫印迹; 小鼠; 1:1000
默克密理博中国表皮生长因子受体抗体(Millipore, 05-484)被用于被用于免疫印迹在人类样本上浓度为1:1000 和 被用于免疫印迹在小鼠样本上浓度为1:1000. Biol Open (2014) ncbi
碧迪BD
小鼠 单克隆(13/EGFR)
  • 免疫印迹; 人类; 图 1b
碧迪BD表皮生长因子受体抗体(BD Biosciences, 610017)被用于被用于免疫印迹在人类样本上 (图 1b). Cancer Res (2017) ncbi
小鼠 单克隆(21/Mena)
  • 免疫组化-石蜡切片; 人类; 图 1a
碧迪BD表皮生长因子受体抗体(BD Bioscience, 610693)被用于被用于免疫组化-石蜡切片在人类样本上 (图 1a). Oncoimmunology (2016) ncbi
小鼠 单克隆(13/EGFR)
  • 免疫印迹; 人类; 图 1
碧迪BD表皮生长因子受体抗体(BD Biosciences, 610017)被用于被用于免疫印迹在人类样本上 (图 1). Oncotarget (2016) ncbi
小鼠 单克隆(13/EGFR)
  • 免疫沉淀; 人类; 图 3
  • 免疫印迹; 人类; 图 2
碧迪BD表皮生长因子受体抗体(BD Biosciences, 610017)被用于被用于免疫沉淀在人类样本上 (图 3) 和 被用于免疫印迹在人类样本上 (图 2). Breast Cancer Res (2016) ncbi
小鼠 单克隆(13/EGFR)
  • 免疫印迹; 人类; 1:500; 图 2b
碧迪BD表皮生长因子受体抗体(BD Bioscience, 610017)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 2b). Nat Commun (2016) ncbi
小鼠 单克隆(21/Mena)
  • 免疫组化-石蜡切片; 人类; 1:1000; 表 1
碧迪BD表皮生长因子受体抗体(BD Biosciences, 610693)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:1000 (表 1). BMC Cancer (2015) ncbi
小鼠 单克隆(13/EGFR)
  • 免疫印迹; 人类; 图 s3
碧迪BD表皮生长因子受体抗体(BD Biosciences, 610017)被用于被用于免疫印迹在人类样本上 (图 s3). Oncotarget (2015) ncbi
小鼠 单克隆(13/EGFR)
  • 免疫印迹; 人类; 图 1
碧迪BD表皮生长因子受体抗体(BD Bioscience, 610016)被用于被用于免疫印迹在人类样本上 (图 1). Oncotarget (2015) ncbi
小鼠 单克隆(13/EGFR)
  • 免疫印迹; 人类
碧迪BD表皮生长因子受体抗体(BD Biosciences, 610017)被用于被用于免疫印迹在人类样本上. BMC Cancer (2015) ncbi
小鼠 单克隆(13/EGFR)
  • 免疫印迹; 人类; 图 4a,b
碧迪BD表皮生长因子受体抗体(BD Biosciences, 610017)被用于被用于免疫印迹在人类样本上 (图 4a,b). Onco Targets Ther (2015) ncbi
小鼠 单克隆(13/EGFR)
  • 免疫印迹; 人类; 图 4
碧迪BD表皮生长因子受体抗体(BD Biosciences, 610016)被用于被用于免疫印迹在人类样本上 (图 4). Carcinogenesis (2014) ncbi
小鼠 单克隆(13/EGFR)
  • 免疫印迹; 人类; 1:1000; 图 7
碧迪BD表皮生长因子受体抗体(BD Biosciences, 610016)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 7). PLoS ONE (2014) ncbi
小鼠 单克隆(13/EGFR)
  • 免疫印迹; 人类; 图 8a
碧迪BD表皮生长因子受体抗体(BD, 610017)被用于被用于免疫印迹在人类样本上 (图 8a). Mol Biol Cell (2014) ncbi
文章列表
  1. Mahameed M, Boukeileh S, Obiedat A, Darawshi O, Dipta P, Rimon A, et al. Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy. Nat Commun. 2020;11:1304 pubmed 出版商
  2. Ayanlaja A, Ji G, Wang J, Gao Y, Cheng B, Kanwore K, et al. Doublecortin undergo nucleocytoplasmic transport via the RanGTPase signaling to promote glioma progression. Cell Commun Signal. 2020;18:24 pubmed 出版商
  3. Rao L, Giannico D, Leone P, Solimando A, Maiorano E, Caporusso C, et al. HB-EGF-EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma. Cancers (Basel). 2020;12: pubmed 出版商
  4. Lee Y, Ho S, Graves J, Xiao Y, Huang S, Lin W. CGRRF1, a growth suppressor, regulates EGFR ubiquitination in breast cancer. Breast Cancer Res. 2019;21:134 pubmed 出版商
  5. Zoi I, Karamouzis M, Xingi E, Sarantis P, Thomaidou D, Lembessis P, et al. Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas. Breast Cancer Res. 2019;21:132 pubmed 出版商
  6. Zeng H, Castillo Cabrera J, Manser M, Lu B, Yang Z, Strande V, et al. Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC. elife. 2019;8: pubmed 出版商
  7. Canon J, Rex K, Saiki A, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217-223 pubmed 出版商
  8. Lundby A, Franciosa G, Emdal K, Refsgaard J, Gnosa S, Bekker Jensen D, et al. Oncogenic Mutations Rewire Signaling Pathways by Switching Protein Recruitment to Phosphotyrosine Sites. Cell. 2019;179:543-560.e26 pubmed 出版商
  9. Nagpal A, Redvers R, Ling X, Ayton S, Fuentes M, Tavancheh E, et al. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis. Breast Cancer Res. 2019;21:94 pubmed 出版商
  10. Sanghvi V, Leibold J, Mina M, Mohan P, Berishaj M, Li Z, et al. The Oncogenic Action of NRF2 Depends on De-glycation by Fructosamine-3-Kinase. Cell. 2019;178:807-819.e21 pubmed 出版商
  11. Hori A, Shimoda M, Naoi Y, Kagara N, Tanei T, Miyake T, et al. Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer. Breast Cancer Res. 2019;21:88 pubmed 出版商
  12. Wen H, Gao S, Wang Y, Ray M, Magnuson M, Wright C, et al. Myeloid cell-derived HB-EGF Drives Tissue Recovery After Pancreatitis. Cell Mol Gastroenterol Hepatol. 2019;: pubmed 出版商
  13. Lee Y, Chen M, Lee J, Zhang J, Lin S, Fu T, et al. Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. Science. 2019;364: pubmed 出版商
  14. Wagner J, Rapsomaniki M, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, et al. A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. Cell. 2019;177:1330-1345.e18 pubmed 出版商
  15. Jeppesen D, Fenix A, Franklin J, Higginbotham J, Zhang Q, Zimmerman L, et al. Reassessment of Exosome Composition. Cell. 2019;177:428-445.e18 pubmed 出版商
  16. Sapmaz A, Berlin I, Bos E, Wijdeven R, Janssen H, Konietzny R, et al. USP32 regulates late endosomal transport and recycling through deubiquitylation of Rab7. Nat Commun. 2019;10:1454 pubmed 出版商
  17. Fearnley G, Young K, Edgar J, Antrobus R, Hay I, Liang W, et al. The homophilic receptor PTPRK selectively dephosphorylates multiple junctional regulators to promote cell-cell adhesion. elife. 2019;8: pubmed 出版商
  18. Drews K, Calgi M, Harrison W, Drews C, Costa Pinheiro P, Shaw J, et al. Glucosylceramidase Maintains Influenza Virus Infection by Regulating Endocytosis. J Virol. 2019;93: pubmed 出版商
  19. Tsai C, Tsai C, Yi J, Kao H, Huang Y, Wang C, et al. Activin A regulates the epidermal growth factor receptor promoter by activating the PI3K/SP1 pathway in oral squamous cell carcinoma cells. Sci Rep. 2019;9:5197 pubmed 出版商
  20. Quinney K, Frankel E, Shankar R, Kasberg W, Luong P, Audhya A. Growth factor stimulation promotes multivesicular endosome biogenesis by prolonging recruitment of the late-acting ESCRT machinery. Proc Natl Acad Sci U S A. 2019;116:6858-6867 pubmed 出版商
  21. Pergu R, Dagar S, Kumar H, Kumar R, Bhattacharya J, Mylavarapu S. The chaperone ERp29 is required for tunneling nanotube formation by stabilizing MSec. J Biol Chem. 2019;294:7177-7193 pubmed 出版商
  22. Greer Y, Gilbert S, Gril B, Narwal R, Peacock Brooks D, Tice D, et al. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer. Breast Cancer Res. 2019;21:27 pubmed 出版商
  23. Chen H, Poran A, Unni A, Huang S, Elemento O, Snoeck H, et al. Generation of pulmonary neuroendocrine cells and SCLC-like tumors from human embryonic stem cells. J Exp Med. 2019;216:674-687 pubmed 出版商
  24. Nava M, Dutta P, Zemke N, Farias Eisner R, Vadgama J, Wu Y. Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets. BMC Med Genomics. 2019;12:32 pubmed 出版商
  25. Kubli S, Bassi C, Roux C, Wakeham A, Göbl C, Zhou W, et al. AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer. Proc Natl Acad Sci U S A. 2019;116:3604-3613 pubmed 出版商
  26. Unni A, Harbourne B, Oh M, Wild S, Ferrarone J, Lockwood W, et al. Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells. elife. 2018;7: pubmed 出版商
  27. Jeong J, Choi J, Kim W, Dann P, Takyar F, Gefter J, et al. Inhibition of ezrin causes PKCα-mediated internalization of erbb2/HER2 tyrosine kinase in breast cancer cells. J Biol Chem. 2019;294:887-901 pubmed 出版商
  28. Lee S, Cho Y, Cha P, Yoon J, Ro E, Jeong W, et al. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab. Exp Mol Med. 2018;50:153 pubmed 出版商
  29. Grohmann M, Wiede F, Dodd G, Gurzov E, Ooi G, Butt T, et al. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC. Cell. 2018;175:1289-1306.e20 pubmed 出版商
  30. Liang C, Ma Y, Yong L, Yang C, Wang P, Liu X, et al. Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma. Cancer Sci. 2019;110:166-179 pubmed 出版商
  31. Gut G, Herrmann M, Pelkmans L. Multiplexed protein maps link subcellular organization to cellular states. Science. 2018;361: pubmed 出版商
  32. Fan P, Narzisi G, Jayaprakash A, Venturini E, Robine N, Smibert P, et al. YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proc Natl Acad Sci U S A. 2018;115:E6030-E6038 pubmed 出版商
  33. Xue Z, Vis D, Bruna A, Sustic T, van Wageningen S, Batra A, et al. MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. Cell Res. 2018;28:719-729 pubmed 出版商
  34. Park J, Kim I, Choi J, Lim H, Shin J, Kim Y, et al. AHNAK Loss in Mice Promotes Type II Pneumocyte Hyperplasia and Lung Tumor Development. Mol Cancer Res. 2018;16:1287-1298 pubmed 出版商
  35. Ng P, Li J, Jeong K, Shao S, Chen H, Tsang Y, et al. Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell. 2018;33:450-462.e10 pubmed 出版商
  36. Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359:920-926 pubmed 出版商
  37. Gstrein T, Edwards A, Přistoupilová A, Leca I, Breuss M, Pilat Carotta S, et al. Mutations in Vps15 perturb neuronal migration in mice and are associated with neurodevelopmental disease in humans. Nat Neurosci. 2018;21:207-217 pubmed 出版商
  38. Park G, Kim D. Cigarette smoke-induced EGFR activation promotes epithelial mesenchymal migration of human retinal pigment epithelial cells through regulation of the FAK-mediated Syk/Src pathway. Mol Med Rep. 2018;17:3563-3574 pubmed 出版商
  39. Oldrini B, Hsieh W, Erdjument Bromage H, Codega P, Carro M, Curiel García A, et al. EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer. Nat Commun. 2017;8:2035 pubmed 出版商
  40. Yu R, Longo J, van Leeuwen J, Mullen P, Ba Alawi W, Haibe Kains B, et al. Statin-Induced Cancer Cell Death Can Be Mechanistically Uncoupled from Prenylation of RAS Family Proteins. Cancer Res. 2018;78:1347-1357 pubmed 出版商
  41. Zeng L, Kang R, Zhu S, Wang X, Cao L, Wang H, et al. ALK is a therapeutic target for lethal sepsis. Sci Transl Med. 2017;9: pubmed 出版商
  42. Mai W, Gosa L, Daniëls V, Ta L, Tsang J, Higgins B, et al. Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma. Nat Med. 2017;23:1342-1351 pubmed 出版商
  43. Liu S, Liu H, Johnston A, Hanna Addams S, Reynoso E, Xiang Y, et al. MLKL forms disulfide bond-dependent amyloid-like polymers to induce necroptosis. Proc Natl Acad Sci U S A. 2017;114:E7450-E7459 pubmed 出版商
  44. Baumann C, Ullrich A, Torka R. GAS6-expressing and self-sustaining cancer cells in 3D spheroids activate the PDK-RSK-mTOR pathway for survival and drug resistance. Mol Oncol. 2017;11:1430-1447 pubmed 出版商
  45. Guo J, Jayaprakash P, Dan J, Wise P, Jang G, Liang C, et al. PRAS40 Connects Microenvironmental Stress Signaling to Exosome-Mediated Secretion. Mol Cell Biol. 2017;37: pubmed 出版商
  46. Laviolette L, Mermoud J, Calvo I, Olson N, Boukhali M, Steinlein O, et al. Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein. Nat Commun. 2017;8:15866 pubmed 出版商
  47. ElHady A, Abdel Halim M, Abadi A, Engel M. Development of Selective Clk1 and -4 Inhibitors for Cellular Depletion of Cancer-Relevant Proteins. J Med Chem. 2017;60:5377-5391 pubmed 出版商
  48. Vaishnavi A, Schubert L, Rix U, Marek L, Le A, Keysar S, et al. EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Res. 2017;77:3551-3563 pubmed 出版商
  49. Xiao Z, Gaertner S, Morresi Hauf A, Genzel R, Duell T, Ullrich A, et al. Metformin Triggers Autophagy to Attenuate Drug-Induced Apoptosis in NSCLC Cells, with Minor Effects on Tumors of Diabetic Patients. Neoplasia. 2017;19:385-395 pubmed 出版商
  50. Bi P, Ramirez Martinez A, Li H, Cannavino J, McAnally J, Shelton J, et al. Control of muscle formation by the fusogenic micropeptide myomixer. Science. 2017;356:323-327 pubmed 出版商
  51. Setty B, Pillay Smiley N, Pool C, Jin Y, Liu Y, Nelin L. Hypoxia-induced proliferation of HeLa cells depends on epidermal growth factor receptor-mediated arginase II induction. Physiol Rep. 2017;5: pubmed 出版商
  52. Solis N, Swidergall M, Bruno V, Gaffen S, Filler S. The Aryl Hydrocarbon Receptor Governs Epithelial Cell Invasion during Oropharyngeal Candidiasis. MBio. 2017;8: pubmed 出版商
  53. Lee H, Kim M, Baek M, Morales L, Jang I, Slaga T, et al. Targeted disruption of TC-PTP in the proliferative compartment augments STAT3 and AKT signaling and skin tumor development. Sci Rep. 2017;7:45077 pubmed 出版商
  54. Manzanares M, Usui A, Campbell D, Dumur C, Maldonado G, Fausther M, et al. Transforming Growth Factors α and β Are Essential for Modeling Cholangiocarcinoma Desmoplasia and Progression in a Three-Dimensional Organotypic Culture Model. Am J Pathol. 2017;187:1068-1092 pubmed 出版商
  55. Gupta A, Anjomani Virmouni S, Koundouros N, Dimitriadi M, Choo Wing R, Valle A, et al. PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation. Mol Cell. 2017;65:999-1013.e7 pubmed 出版商
  56. Cherniack A, Shen H, Walter V, Stewart C, Murray B, Bowlby R, et al. Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell. 2017;31:411-423 pubmed 出版商
  57. Shizu R, Osabe M, Perera L, Moore R, Sueyoshi T, Negishi M. Phosphorylated Nuclear Receptor CAR Forms a Homodimer To Repress Its Constitutive Activity for Ligand Activation. Mol Cell Biol. 2017;37: pubmed 出版商
  58. Li K, Mo C, Gong D, Chen Y, Huang Z, Li Y, et al. DDX17 nucleocytoplasmic shuttling promotes acquired gefitinib resistance in non-small cell lung cancer cells via activation of β-catenin. Cancer Lett. 2017;400:194-202 pubmed 出版商
  59. Shi J, Bei Y, Kong X, Liu X, Lei Z, Xu T, et al. miR-17-3p Contributes to Exercise-Induced Cardiac Growth and Protects against Myocardial Ischemia-Reperfusion Injury. Theranostics. 2017;7:664-676 pubmed 出版商
  60. Gomes de Castro M, Hobartner C, Opazo F. Aptamers provide superior stainings of cellular receptors studied under super-resolution microscopy. PLoS ONE. 2017;12:e0173050 pubmed 出版商
  61. Schumacher M, Hedl M, Abraham C, Bernard J, Lozano P, Hsieh J, et al. ErbB4 signaling stimulates pro-inflammatory macrophage apoptosis and limits colonic inflammation. Cell Death Dis. 2017;8:e2622 pubmed 出版商
  62. Peiris D, Spector A, Lomax Browne H, Azimi T, Ramesh B, Loizidou M, et al. Cellular glycosylation affects Herceptin binding and sensitivity of breast cancer cells to doxorubicin and growth factors. Sci Rep. 2017;7:43006 pubmed 出版商
  63. Radder J, Zhang Y, Gregory A, Yu S, Kelly N, Leader J, et al. Extreme Trait Whole-Genome Sequencing Identifies PTPRO as a Novel Candidate Gene in Emphysema with Severe Airflow Obstruction. Am J Respir Crit Care Med. 2017;196:159-171 pubmed 出版商
  64. Furukawa S, Nagaike M, Ozaki K. Databases for technical aspects of immunohistochemistry. J Toxicol Pathol. 2017;30:79-107 pubmed 出版商
  65. Dong Q, Fu L, Zhao Y, Tan S, Wang E. Derlin-1 overexpression confers poor prognosis in muscle invasive bladder cancer and contributes to chemoresistance and invasion through PI3K/AKT and ERK/MMP signaling. Oncotarget. 2017;8:17059-17069 pubmed 出版商
  66. Way G, Allaway R, Bouley S, Fadul C, Sanchez Y, Greene C. A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. BMC Genomics. 2017;18:127 pubmed 出版商
  67. Duhachek Muggy S, Qi Y, Wise R, Alyahya L, Li H, Hodge J, et al. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer. Mol Cancer. 2017;16:32 pubmed 出版商
  68. Melchionna R, Iapicca P, Di Modugno F, Trono P, Sperduti I, Fassan M, et al. The pattern of hMENA isoforms is regulated by TGF-?1 in pancreatic cancer and may predict patient outcome. Oncoimmunology. 2016;5:e1221556 pubmed 出版商
  69. Xu J, Zhang X, Wang H, Ge S, Gao T, Song L, et al. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition. Biomed Pharmacother. 2017;88:421-429 pubmed 出版商
  70. Ma K, Fu W, Tang M, Zhang C, Hou T, Li R, et al. PTK2-mediated degradation of ATG3 impedes cancer cells susceptible to DNA damage treatment. Autophagy. 2017;13:579-591 pubmed 出版商
  71. Cao H, Yu S, Chen D, Jing C, Wang Z, Ma R, et al. Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR-TKI treatment. FEBS Open Bio. 2017;7:35-43 pubmed 出版商
  72. Huang S, Mao J, Ding K, Zhou Y, Zeng X, Yang W, et al. Polysaccharides from Ganoderma lucidum Promote Cognitive Function and Neural Progenitor Proliferation in Mouse Model of Alzheimer's Disease. Stem Cell Reports. 2017;8:84-94 pubmed 出版商
  73. Muranen T, Iwanicki M, Curry N, Hwang J, DuBois C, Coloff J, et al. Starved epithelial cells uptake extracellular matrix for survival. Nat Commun. 2017;8:13989 pubmed 出版商
  74. Zhao B, Hu W, Kumar S, Gonyo P, Rana U, Liu Z, et al. The Nogo-B receptor promotes Ras plasma membrane localization and activation. Oncogene. 2017;36:3406-3416 pubmed 出版商
  75. Li J, Liu B, Shi Y, Xie K, Yin H, Yan L, et al. CXCL4 Contributes to the Pathogenesis of Chronic Liver Allograft Dysfunction. J Immunol Res. 2016;2016:9276986 pubmed 出版商
  76. Khelwatty S, Essapen S, Bagwan I, Green M, Seddon A, Modjtahedi H. The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer. Oncotarget. 2017;8:7666-7677 pubmed 出版商
  77. Hill S, Nesser N, Johnson Camacho K, Jeffress M, Johnson A, Boniface C, et al. Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling. Cell Syst. 2017;4:73-83.e10 pubmed 出版商
  78. Tian X, Ye M, Cao Y, Wang C. Losartan Improves Palmitate-Induced Insulin Resistance in 3T3-L1 Adipocytes Through Upregulation of Src Phosphorylation. Exp Clin Endocrinol Diabetes. 2017;125:136-140 pubmed 出版商
  79. Li C, Luo X, Zhao S, Siu G, Liang Y, Chan H, et al. COPI-TRAPPII activates Rab18 and regulates its lipid droplet association. EMBO J. 2017;36:441-457 pubmed 出版商
  80. Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan X, et al. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. Oncotarget. 2017;8:9251-9266 pubmed 出版商
  81. Wymant J, Hiscox S, Westwell A, Urbé S, Clague M, Jones A. The Role of BCA2 in the Endocytic Trafficking of EGFR and Significance as a Prognostic Biomarker in Cancer. J Cancer. 2016;7:2388-2407 pubmed
  82. Kneissl J, Hartmann A, Pfarr N, Erlmeier F, Lorber T, Keller S, et al. Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines. J Cancer Res Clin Oncol. 2017;143:573-600 pubmed 出版商
  83. Mukhopadhyay C, Triplett A, Bargar T, HECKMAN C, Wagner K, Naramura M. Casitas B-cell lymphoma (Cbl) proteins protect mammary epithelial cells from proteotoxicity of active c-Src accumulation. Proc Natl Acad Sci U S A. 2016;113:E8228-E8237 pubmed 出版商
  84. Lee H, Khan S, Khaliqdina S, Altintas M, Grahammer F, Zhao J, et al. Absence of miR-146a in Podocytes Increases Risk of Diabetic Glomerulopathy via Up-regulation of ErbB4 and Notch-1. J Biol Chem. 2017;292:732-747 pubmed 出版商
  85. Zhang Y, Yang J, Ding M, Li L, Lu Z, Zhang Q, et al. Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC. Oncol Lett. 2016;12:3241-3249 pubmed
  86. Scharaw S, Iskar M, Ori A, Boncompain G, Laketa V, Poser I, et al. The endosomal transcriptional regulator RNF11 integrates degradation and transport of EGFR. J Cell Biol. 2016;215:543-558 pubmed
  87. Reuther C, Heinzle V, Nölting S, Herterich S, Hahner S, Halilovic E, et al. The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1. Neuroendocrinology. 2018;106:1-19 pubmed 出版商
  88. Du M, Zhang Y, Mao Y, Mou J, Zhao J, Xue Q, et al. MiR-33a suppresses proliferation of NSCLC cells via targeting METTL3 mRNA. Biochem Biophys Res Commun. 2017;482:582-589 pubmed 出版商
  89. Amessou M, Ebrahim A, Dilly A, Joseph M, Tabolina M, Chukkapalli S, et al. Spatio-temporal regulation of EGFR signaling by the Eps15 homology domain-containing protein 3 (EHD3). Oncotarget. 2016;7:79203-79216 pubmed 出版商
  90. Zangi L, Oliveira M, Ye L, Ma Q, Sultana N, Hadas Y, et al. Insulin-Like Growth Factor 1 Receptor-Dependent Pathway Drives Epicardial Adipose Tissue Formation After Myocardial Injury. Circulation. 2017;135:59-72 pubmed 出版商
  91. Jaber N, Mohd Naim N, Wang Z, Deleon J, Kim S, Zhong H, et al. Vps34 regulates Rab7 and late endocytic trafficking through recruitment of the GTPase-activating protein Armus. J Cell Sci. 2016;129:4424-4435 pubmed
  92. Day K, Lorenzatti Hiles G, Kozminsky M, Dawsey S, Paul A, Broses L, et al. HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. Cancer Res. 2017;77:74-85 pubmed 出版商
  93. Grugan K, Dorn K, Jarantow S, Bushey B, Pardinas J, Laquerre S, et al. Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells. MAbs. 2017;9:114-126 pubmed 出版商
  94. Parrales A, Ranjan A, Iyer S, Padhye S, Weir S, Roy A, et al. DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway. Nat Cell Biol. 2016;18:1233-1243 pubmed 出版商
  95. Yong K, Li A, Ou W, Hong C, Zhao W, Wang F, et al. Targeting SALL4 by entinostat in lung cancer. Oncotarget. 2016;7:75425-75440 pubmed 出版商
  96. Mitra S, Ghosh B, Gayen N, Roy J, Mandal A. Bipartite Role of Heat Shock Protein 90 (Hsp90) Keeps CRAF Kinase Poised for Activation. J Biol Chem. 2016;291:24579-24593 pubmed
  97. Cizmecioglu O, Ni J, Xie S, Zhao J, Roberts T. Rac1-mediated membrane raft localization of PI3K/p110? is required for its activation by GPCRs or PTEN loss. elife. 2016;5: pubmed 出版商
  98. Kang S, Wang Y, Reder N, Liu J. Multiplexed Molecular Imaging of Biomarker-Targeted SERS Nanoparticles on Fresh Tissue Specimens with Channel-Compressed Spectrometry. PLoS ONE. 2016;11:e0163473 pubmed 出版商
  99. Truong D, Puleo J, Llave A, Mouneimne G, Kamm R, Nikkhah M. Breast Cancer Cell Invasion into a Three Dimensional Tumor-Stroma Microenvironment. Sci Rep. 2016;6:34094 pubmed 出版商
  100. Horn T, Ferretti S, Ebel N, Tam A, Ho S, Harbinski F, et al. High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells. Cancer Res. 2016;76:6950-6963 pubmed
  101. Hang Q, Isaji T, Hou S, Zhou Y, Fukuda T, Gu J. N-Glycosylation of integrin ?5 acts as a switch for EGFR-mediated complex formation of integrin ?5?1 to ?6?4. Sci Rep. 2016;6:33507 pubmed 出版商
  102. Chen P, Qin L, Li G, Tellides G, Simons M. Fibroblast growth factor (FGF) signaling regulates transforming growth factor beta (TGF?)-dependent smooth muscle cell phenotype modulation. Sci Rep. 2016;6:33407 pubmed 出版商
  103. Edinger N, Lebendiker M, Klein S, Zigler M, Langut Y, Levitzki A. Targeting polyIC to EGFR over-expressing cells using a dsRNA binding protein domain tethered to EGF. PLoS ONE. 2016;11:e0162321 pubmed 出版商
  104. Xu J, Xiong G, Cao Z, Huang H, Wang T, You L, et al. PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value. J Exp Clin Cancer Res. 2016;35:133 pubmed 出版商
  105. Kimani S, Kumar S, Davra V, Chang Y, Kasikara C, Geng K, et al. Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase. Cell Commun Signal. 2016;14:19 pubmed 出版商
  106. Mair B, Konopka T, Kerzendorfer C, Sleiman K, Salic S, Serra V, et al. Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity. PLoS Genet. 2016;12:e1006279 pubmed 出版商
  107. Jiang M, Qiu J, Zhang L, Lu D, Long M, Chen L, et al. Changes in tension regulates proliferation and migration of fibroblasts by remodeling expression of ECM proteins. Exp Ther Med. 2016;12:1542-1550 pubmed
  108. Li C, Lim S, Xia W, Lee H, Chan L, Kuo C, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632 pubmed 出版商
  109. Jaako K, Waniek A, Parik K, Klimaviciusa L, Aonurm Helm A, Noortoots A, et al. Prolyl endopeptidase is involved in the degradation of neural cell adhesion molecules in vitro. J Cell Sci. 2016;129:3792-3802 pubmed
  110. Padhan N, Nordling T, Sundstrom M, Akerud P, Birgisson H, Nygren P, et al. High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer. BMC Cancer. 2016;16:683 pubmed 出版商
  111. Sun M, Cai J, Anderson R, Sun Y. Type I ? Phosphatidylinositol Phosphate 5-Kinase i5 Controls the Ubiquitination and Degradation of the Tumor Suppressor Mitogen-inducible Gene 6. J Biol Chem. 2016;291:21461-21473 pubmed
  112. Jordan N, Bardia A, Wittner B, Benes C, Ligorio M, Zheng Y, et al. HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature. 2016;537:102-106 pubmed 出版商
  113. LAW M, Ferreira R, Davis B, Higgins P, Kim J, Castellano R, et al. CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment. Breast Cancer Res. 2016;18:80 pubmed 出版商
  114. Salema V, Mañas C, Cerdán L, Piñero Lambea C, Marín E, Roovers R, et al. High affinity nanobodies against human epidermal growth factor receptor selected on cells by E. coli display. MAbs. 2016;8:1286-1301 pubmed
  115. Im J, Yoon S, Kim B, Ban H, Won K, Chung K, et al. DNA damage induced apoptosis suppressor (DDIAS) is upregulated via ERK5/MEF2B signaling and promotes ?-catenin-mediated invasion. Biochim Biophys Acta. 2016;1859:1449-1458 pubmed 出版商
  116. Carino A, Graziosi L, D Amore C, Cipriani S, Marchianò S, Marino E, et al. The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines. Oncotarget. 2016;7:61021-61035 pubmed 出版商
  117. Zhang Y, Velez Delgado A, Mathew E, Li D, Mendez F, Flannagan K, et al. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut. 2017;66:124-136 pubmed 出版商
  118. Deblois G, Smith H, Tam I, Gravel S, Caron M, Savage P, et al. ERR? mediates metabolic adaptations driving lapatinib resistance in breast cancer. Nat Commun. 2016;7:12156 pubmed 出版商
  119. Grassi M, Palma C, Thomé C, Lanfredi G, Poersch A, Faça V. Proteomic analysis of ovarian cancer cells during epithelial-mesenchymal transition (EMT) induced by epidermal growth factor (EGF) reveals mechanisms of cell cycle control. J Proteomics. 2017;151:2-11 pubmed 出版商
  120. Huang C, Lee C, Lin H, Chang J. Cathepsin S attenuates endosomal EGFR signalling: A mechanical rationale for the combination of cathepsin S and EGFR tyrosine kinase inhibitors. Sci Rep. 2016;6:29256 pubmed 出版商
  121. Edmondson R, Adcock A, Yang L. Influence of Matrices on 3D-Cultured Prostate Cancer Cells' Drug Response and Expression of Drug-Action Associated Proteins. PLoS ONE. 2016;11:e0158116 pubmed 出版商
  122. Tisza M, Zhao W, Fuentes J, Prijic S, Chen X, Levental I, et al. Motility and stem cell properties induced by the epithelial-mesenchymal transition require destabilization of lipid rafts. Oncotarget. 2016;7:51553-51568 pubmed 出版商
  123. Wang J, Farris A, Xu K, Wang P, Zhang X, Duong D, et al. GPRC5A suppresses protein synthesis at the endoplasmic reticulum to prevent radiation-induced lung tumorigenesis. Nat Commun. 2016;7:11795 pubmed 出版商
  124. Schütz I, López Hernández T, Gao Q, Puchkov D, Jabs S, Nordmeyer D, et al. Lysosomal Dysfunction Caused by Cellular Accumulation of Silica Nanoparticles. J Biol Chem. 2016;291:14170-84 pubmed 出版商
  125. Chamberland J, Antonow L, Dias Santos M, Ritter B. NECAP2 controls clathrin coat recruitment to early endosomes for fast endocytic recycling. J Cell Sci. 2016;129:2625-37 pubmed 出版商
  126. He F, Wei L, Luo W, Liao Z, Li B, Zhou X, et al. Glutaredoxin 3 promotes nasopharyngeal carcinoma growth and metastasis via EGFR/Akt pathway and independent of ROS. Oncotarget. 2016;7:37000-37012 pubmed 出版商
  127. Currier M, Lee S, Stobart C, Hotard A, Villenave R, Meng J, et al. EGFR Interacts with the Fusion Protein of Respiratory Syncytial Virus Strain 2-20 and Mediates Infection and Mucin Expression. PLoS Pathog. 2016;12:e1005622 pubmed 出版商
  128. Francavilla C, Papetti M, Rigbolt K, Pedersen A, Sigurdsson J, Cazzamali G, et al. Multilayered proteomics reveals molecular switches dictating ligand-dependent EGFR trafficking. Nat Struct Mol Biol. 2016;23:608-18 pubmed 出版商
  129. Rapiteanu R, Davis L, Williamson J, Timms R, Paul Luzio J, Lehner P. A Genetic Screen Identifies a Critical Role for the WDR81-WDR91 Complex in the Trafficking and Degradation of Tetherin. Traffic. 2016;17:940-58 pubmed 出版商
  130. Lin S, Choe J, Du P, Triboulet R, Gregory R. The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells. Mol Cell. 2016;62:335-345 pubmed 出版商
  131. Jahani Asl A, Yin H, Soleimani V, Haque T, Luchman H, Chang N, et al. Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. Nat Neurosci. 2016;19:798-806 pubmed 出版商
  132. Thomas J, Chhuy Hy L, Andrykovich K, Moos M. SMOC Binds to Pro-EGF, but Does Not Induce Erk Phosphorylation via the EGFR. PLoS ONE. 2016;11:e0154294 pubmed 出版商
  133. Engel B, Bowser J, Broaddus R, Carson D. MUC1 stimulates EGFR expression and function in endometrial cancer. Oncotarget. 2016;7:32796-809 pubmed 出版商
  134. Hatanaka M, Higashi Y, Kawai K, Su J, Zeng W, Chen X, et al. CD147-targeted siRNA in A375 malignant melanoma cells induces the phosphorylation of EGFR and downregulates cdc25C and MEK phosphorylation. Oncol Lett. 2016;11:2424-2428 pubmed
  135. Jadwin J, Oh D, Curran T, Ogiue Ikeda M, Jia L, White F, et al. Time-resolved multimodal analysis of Src Homology 2 (SH2) domain binding in signaling by receptor tyrosine kinases. elife. 2016;5:e11835 pubmed 出版商
  136. Xing M, Wang X, Chi Y, Zhou D. Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab. Oncotarget. 2016;7:28262-72 pubmed 出版商
  137. Balasooriya G, Johnson J, Basson M, Rawlins E. An FGFR1-SPRY2 Signaling Axis Limits Basal Cell Proliferation in the Steady-State Airway Epithelium. Dev Cell. 2016;37:85-97 pubmed 出版商
  138. Phelps Polirer K, Abt M, Smith D, Yeh E. Co-Targeting of JNK and HUNK in Resistant HER2-Positive Breast Cancer. PLoS ONE. 2016;11:e0153025 pubmed 出版商
  139. Huang M, Liu T, Ma P, Mitteer R, Zhang Z, Kim H, et al. c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma. J Clin Invest. 2016;126:1801-14 pubmed 出版商
  140. Krampitz G, George B, Willingham S, Volkmer J, Weiskopf K, Jahchan N, et al. Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors. Proc Natl Acad Sci U S A. 2016;113:4464-9 pubmed 出版商
  141. Gschweitl M, Ulbricht A, Barnes C, Enchev R, Stoffel Studer I, Meyer Schaller N, et al. A SPOPL/Cullin-3 ubiquitin ligase complex regulates endocytic trafficking by targeting EPS15 at endosomes. elife. 2016;5:e13841 pubmed 出版商
  142. Mancini M, Lien E, Toker A. Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis. Oncotarget. 2016;7:17301-13 pubmed 出版商
  143. Wen Y, Li H, Zeng Y, Wen W, Pendleton K, Lui V, et al. MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin. Oncotarget. 2016;7:23300-11 pubmed 出版商
  144. Ezawa I, Sawai Y, Kawase T, Okabe A, Tsutsumi S, Ichikawa H, et al. Novel p53 target gene FUCA1 encodes a fucosidase and regulates growth and survival of cancer cells. Cancer Sci. 2016;107:734-45 pubmed 出版商
  145. Ananthula S, Sinha A, El Gassim M, Batth S, Marshall G, Gardner L, et al. Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers. Oncotarget. 2016;7:20869-89 pubmed 出版商
  146. Kabe Y, Nakane T, Koike I, Yamamoto T, Sugiura Y, Harada E, et al. Haem-dependent dimerization of PGRMC1/Sigma-2 receptor facilitates cancer proliferation and chemoresistance. Nat Commun. 2016;7:11030 pubmed 出版商
  147. Atiq R, Hertz R, Eldad S, Smeir E, Bar Tana J. Suppression of B-Raf(V600E) cancers by MAPK hyper-activation. Oncotarget. 2016;7:18694-704 pubmed 出版商
  148. SaygideÄŸer Kont Y, Minas T, Jones H, Hour S, Çelik H, Temel I, et al. Ezrin Enhances EGFR Signaling and Modulates Erlotinib Sensitivity in Non-Small Cell Lung Cancer Cells. Neoplasia. 2016;18:111-20 pubmed 出版商
  149. Haven B, Heilig E, Donham C, Settles M, Vasilevsky N, Owen K. Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. elife. 2016;5: pubmed 出版商
  150. Li H, Shen P, Liang Y, Zhang F. Fibroblastic reticular cell tumor of the breast: A case report and review of the literature. Exp Ther Med. 2016;11:561-564 pubmed
  151. Wang Y, Kang S, Khan A, Ruttner G, Leigh S, Murray M, et al. Quantitative molecular phenotyping with topically applied SERS nanoparticles for intraoperative guidance of breast cancer lumpectomy. Sci Rep. 2016;6:21242 pubmed 出版商
  152. Kim D, Helfman D. Loss of MLCK leads to disruption of cell-cell adhesion and invasive behavior of breast epithelial cells via increased expression of EGFR and ERK/JNK signaling. Oncogene. 2016;35:4495-508 pubmed 出版商
  153. Hennig A, Markwart R, Wolff K, Schubert K, Cui Y, Prior I, et al. Feedback activation of neurofibromin terminates growth factor-induced Ras activation. Cell Commun Signal. 2016;14:5 pubmed 出版商
  154. Arena S, Siravegna G, Mussolin B, Kearns J, Wolf B, Misale S, et al. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci Transl Med. 2016;8:324ra14 pubmed 出版商
  155. Nakazawa M, Eisinger Mathason T, Sadri N, Ochocki J, Gade T, Amin R, et al. Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth. Nat Commun. 2016;7:10539 pubmed 出版商
  156. Hayashi H, Al Mamun A, Sakima M, Sato M. Activator of G-protein signaling 8 is involved in VEGF-mediated signal processing during angiogenesis. J Cell Sci. 2016;129:1210-22 pubmed 出版商
  157. Derangère V, Fumet J, Boidot R, Bengrine L, Limagne E, Chevriaux A, et al. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?. Oncotarget. 2016;7:9309-21 pubmed 出版商
  158. Evans M, Sauer S, Nath S, Robinson T, Morse M, Devi G. X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity. Cell Death Dis. 2016;7:e2073 pubmed 出版商
  159. Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam K, et al. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS ONE. 2016;11:e0147344 pubmed 出版商
  160. Roßner F, Gieseler C, Morkel M, Royer H, Rivera M, Bläker H, et al. Uncoupling of EGFR-RAS signaling and nuclear localization of YBX1 in colorectal cancer. Oncogenesis. 2016;5:e187 pubmed 出版商
  161. Kooijmans S, Fliervoet L, van der Meel R, Fens M, Heijnen H, van Bergen En Henegouwen P, et al. PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. J Control Release. 2016;224:77-85 pubmed 出版商
  162. Ketel K, Krauss M, Nicot A, Puchkov D, Wieffer M, Müller R, et al. A phosphoinositide conversion mechanism for exit from endosomes. Nature. 2016;529:408-12 pubmed 出版商
  163. Liu Q, Sanai N, Jin W, La Cava A, Van Kaer L, Shi F. Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation. Nat Neurosci. 2016;19:243-52 pubmed 出版商
  164. Lin A, Li C, Xing Z, Hu Q, Liang K, Han L, et al. The LINK-A lncRNA activates normoxic HIF1? signalling in triple-negative breast cancer. Nat Cell Biol. 2016;18:213-24 pubmed 出版商
  165. Jeong J, VanHouten J, Dann P, Kim W, Sullivan C, Yu H, et al. PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer. Proc Natl Acad Sci U S A. 2016;113:E282-90 pubmed 出版商
  166. Matalkah F, Martin E, Zhao H, Agazie Y. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer. Breast Cancer Res. 2016;18:2 pubmed 出版商
  167. Yamaguchi T, Lu C, Ida L, Yanagisawa K, Usukura J, Cheng J, et al. ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1. Nat Commun. 2016;7:10060 pubmed 出版商
  168. Salova A, Belyaeva T, Leontieva E, Zlobina M, Kharchenko M, Kornilova E. Quantum dots implementation as a label for analysis of early stages of EGF receptor endocytosis: a comparative study on cultured cells. Oncotarget. 2016;7:6029-47 pubmed 出版商
  169. Hessmann E, Zhang J, Chen N, Hasselluhn M, Liou G, Storz P, et al. NFATc4 Regulates Sox9 Gene Expression in Acinar Cell Plasticity and Pancreatic Cancer Initiation. Stem Cells Int. 2016;2016:5272498 pubmed 出版商
  170. Roshan A, Murai K, Fowler J, Simons B, Nikolaidou Neokosmidou V, Jones P. Human keratinocytes have two interconvertible modes of proliferation. Nat Cell Biol. 2016;18:145-56 pubmed 出版商
  171. Baumdick M, Brüggemann Y, Schmick M, Xouri G, Sabet O, Davis L, et al. EGF-dependent re-routing of vesicular recycling switches spontaneous phosphorylation suppression to EGFR signaling. elife. 2015;4: pubmed 出版商
  172. Chen J, Chen Y, Yen C, Chen W, Huang W. HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3. Oncotarget. 2016;7:473-89 pubmed 出版商
  173. Diersch S, Wirth M, Schneeweis C, Jörs S, Geisler F, Siveke J, et al. Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells. Oncogene. 2016;35:3880-6 pubmed 出版商
  174. Ponti D, Bastianelli D, Rosa P, Pacini L, Ibrahim M, Rendina E, et al. The expression of B23 and EGR1 proteins is functionally linked in tumor cells under stress conditions. BMC Cell Biol. 2015;16:27 pubmed 出版商
  175. Gao L, Jiang Y, Mu L, Liu Y, Wang F, Wang P, et al. Efficient Generation of Mice with Consistent Transgene Expression by FEEST. Sci Rep. 2015;5:16284 pubmed 出版商
  176. Oprea T, Sklar L, Agola J, Guo Y, Silberberg M, Roxby J, et al. Novel Activities of Select NSAID R-Enantiomers against Rac1 and Cdc42 GTPases. PLoS ONE. 2015;10:e0142182 pubmed 出版商
  177. Chen S, Chen Y, Chen B, Cai Y, Zou Z, Wang J, et al. Plumbagin Ameliorates CCl 4 -Induced Hepatic Fibrosis in Rats via the Epidermal Growth Factor Receptor Signaling Pathway. Evid Based Complement Alternat Med. 2015;2015:645727 pubmed 出版商
  178. Majumder P, Chakrabarti O. Mahogunin regulates fusion between amphisomes/MVBs and lysosomes via ubiquitination of TSG101. Cell Death Dis. 2015;6:e1970 pubmed 出版商
  179. Nikonova A, Deneka A, Eckman L, Kopp M, Hensley H, Egleston B, et al. Opposing Effects of Inhibitors of Aurora-A and EGFR in Autosomal-Dominant Polycystic Kidney Disease. Front Oncol. 2015;5:228 pubmed 出版商
  180. Zomerman W, Plasschaert S, Diks S, Lourens H, Meeuwsen de Boer T, Hoving E, et al. Exogenous HGF Bypasses the Effects of ErbB Inhibition on Tumor Cell Viability in Medulloblastoma Cell Lines. PLoS ONE. 2015;10:e0141381 pubmed 出版商
  181. Dong Y, Hou W, Li Y, Liu D, Hao G, Zhang H, et al. Unexpected requirement for a binding partner of the syntaxin family in phagocytosis by murine testicular Sertoli cells. Cell Death Differ. 2016;23:787-800 pubmed 出版商
  182. Yang C, Lowther K, Lalioti M, Seli E. Embryonic Poly(A)-Binding Protein (EPAB) Is Required for Granulosa Cell EGF Signaling and Cumulus Expansion in Female Mice. Endocrinology. 2016;157:405-16 pubmed 出版商
  183. Bertrand T, Lesept F, Chevilley A, Lenoir S, Aimable M, Briens A, et al. Conformations of tissue plasminogen activator (tPA) orchestrate neuronal survival by a crosstalk between EGFR and NMDAR. Cell Death Dis. 2015;6:e1924 pubmed 出版商
  184. Liu F, Hon G, Villa G, Turner K, Ikegami S, Yang H, et al. EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. Mol Cell. 2015;60:307-18 pubmed 出版商
  185. Kuo H, Hsu H, Chen Y, Chang Y, Liu F, Wu C. Galectin-3 modulates the EGFR signalling-mediated regulation of Sox2 expression via c-Myc in lung cancer. Glycobiology. 2016;26:155-65 pubmed 出版商
  186. Donzelli S, Mori F, Bellissimo T, Sacconi A, Casini B, Frixa T, et al. Epigenetic silencing of miR-145-5p contributes to brain metastasis. Oncotarget. 2015;6:35183-201 pubmed 出版商
  187. Mehner C, Oberg A, Kalli K, Nassar A, Hockla A, Pendlebury D, et al. Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers. Oncotarget. 2015;6:35737-54 pubmed 出版商
  188. Panvichian R, Tantiwetrueangdet A, Sornmayura P, Leelaudomlipi S. Missense Mutations in Exons 18-24 of EGFR in Hepatocellular Carcinoma Tissues. Biomed Res Int. 2015;2015:171845 pubmed 出版商
  189. Cecchetti S, Bortolomai I, Ferri R, Mercurio L, Canevari S, Podo F, et al. Inhibition of Phosphatidylcholine-Specific Phospholipase C Interferes with Proliferation and Survival of Tumor Initiating Cells in Squamous Cell Carcinoma. PLoS ONE. 2015;10:e0136120 pubmed 出版商
  190. Misale S, Bozic I, Tong J, Peraza Penton A, Lallo A, Baldi F, et al. Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nat Commun. 2015;6:8305 pubmed 出版商
  191. Bollu L, Katreddy R, Blessing A, Pham N, Zheng B, Wu X, et al. Intracellular activation of EGFR by fatty acid synthase dependent palmitoylation. Oncotarget. 2015;6:34992-5003 pubmed 出版商
  192. Darr J, Klochendler A, Isaac S, Geiger T, Geiger T, Eden A. Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells. Mol Cancer. 2015;14:167 pubmed 出版商
  193. Kitatani K, Usui T, Sriraman S, Toyoshima M, Ishibashi M, Shigeta S, et al. Ceramide limits phosphatidylinositol-3-kinase C2β-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid. Oncogene. 2016;35:2801-12 pubmed 出版商
  194. Taketa D, Nydam M, Langenbacher A, Rodriguez D, Sanders E, De Tomaso A. Molecular evolution and in vitro characterization of Botryllus histocompatibility factor. Immunogenetics. 2015;67:605-23 pubmed 出版商
  195. Vennin C, Spruyt N, Dahmani F, Julien S, Bertucci F, Finetti P, et al. H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. Oncotarget. 2015;6:29209-23 pubmed 出版商
  196. Valley C, Arndt Jovin D, Karedla N, Steinkamp M, Chizhik A, Hlavacek W, et al. Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer. Mol Biol Cell. 2015;26:4087-99 pubmed 出版商
  197. Wu Y, Deng W, Klinke D. Exosomes: improved methods to characterize their morphology, RNA content, and surface protein biomarkers. Analyst. 2015;140:6631-42 pubmed 出版商
  198. Fu Y, Cruz Monserrate Z, Helen Lin H, Chung Y, Ji B, Lin S, et al. Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype. Sci Rep. 2015;5:13347 pubmed 出版商
  199. Morancho B, Martínez Barriocanal Ã, Villanueva J, Arribas J. Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence. Breast Cancer Res. 2015;17:106 pubmed 出版商
  200. Zhen Y, Li W. Impairment of autophagosome-lysosome fusion in the buff mutant mice with the VPS33A(D251E) mutation. Autophagy. 2015;11:1608-22 pubmed 出版商
  201. Tang Y, Ye M, Du Y, Qiu X, Lv X, Yang W, et al. EGFR signaling upregulates surface expression of the GluN2B-containing NMDA receptor and contributes to long-term potentiation in the hippocampus. Neuroscience. 2015;304:109-21 pubmed 出版商
  202. Li W, Qiu Y, Zhang H, Tian X, Fang W. P2Y2 Receptor and EGFR Cooperate to Promote Prostate Cancer Cell Invasion via ERK1/2 Pathway. PLoS ONE. 2015;10:e0133165 pubmed 出版商
  203. Forse C, Agarwal S, Pinnaduwage D, Gertler F, Condeelis J, Lin J, et al. Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer. BMC Cancer. 2015;15:483 pubmed 出版商
  204. Dombernowsky S, Samsøe Petersen J, Petersen C, Instrell R, Hedegaard A, Thomas L, et al. The sorting protein PACS-2 promotes ErbB signalling by regulating recycling of the metalloproteinase ADAM17. Nat Commun. 2015;6:7518 pubmed 出版商
  205. Yang L, Li Y, Bhattacharya A, Zhang Y. Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant. EBioMedicine. 2015;2:396-405 pubmed
  206. Hutchinson K, Johnson D, Johnson A, Sanchez V, Kuba M, Lu P, et al. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget. 2015;6:22348-60 pubmed
  207. Ma S, Yin N, Qi X, Pfister S, Zhang M, Ma R, et al. Tyrosine dephosphorylation enhances the therapeutic target activity of epidermal growth factor receptor (EGFR) by disrupting its interaction with estrogen receptor (ER). Oncotarget. 2015;6:13320-33 pubmed
  208. Engel B, Constantinou P, Sablatura L, Doty N, Carson D, Farach Carson M, et al. Multilayered, Hyaluronic Acid-Based Hydrogel Formulations Suitable for Automated 3D High Throughput Drug Screening of Cancer-Stromal Cell Cocultures. Adv Healthc Mater. 2015;4:1664-74 pubmed 出版商
  209. Jäger W, Xue H, Hayashi T, Janssen C, Awrey S, Wyatt A, et al. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. Oncotarget. 2015;6:21522-32 pubmed
  210. Min H, Yun H, Lee J, Lee H, Cho J, Jang H, et al. Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer. Mol Cancer. 2015;14:113 pubmed 出版商
  211. Tréhoux S, Lahdaoui F, Delpu Y, Renaud F, Leteurtre E, Torrisani J, et al. Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. Biochim Biophys Acta. 2015;1853:2392-403 pubmed 出版商
  212. Chen C, Kim K, Lau L. The matricellular protein CCN1 suppresses hepatocarcinogenesis by inhibiting compensatory proliferation. Oncogene. 2016;35:1314-23 pubmed 出版商
  213. Li T, Lu H, Mukherjee D, Lahiri S, Shen C, Yu L, et al. Identification of epidermal growth factor receptor and its inhibitory microRNA141 as novel targets of Krüppel-like factor 8 in breast cancer. Oncotarget. 2015;6:21428-42 pubmed
  214. Korotkevych N, Labyntsev A, Kolybo D, Komisarenko S. The Soluble Heparin-Binding EGF-Like Growth Factor Stimulates EGF Receptor Trafficking to the Nucleus. PLoS ONE. 2015;10:e0127887 pubmed 出版商
  215. Ramirez U, Nikonova A, Liu H, Pecherskaya A, Lawrence S, Serebriiskii I, et al. Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization. BMC Cancer. 2015;15:436 pubmed 出版商
  216. Li L, Qi L, Liang Z, Song W, Liu Y, Wang Y, et al. Transforming growth factor-β1 induces EMT by the transactivation of epidermal growth factor signaling through HA/CD44 in lung and breast cancer cells. Int J Mol Med. 2015;36:113-22 pubmed 出版商
  217. Teng Y, Radde B, Litchfield L, Ivanova M, Prough R, Clark B, et al. Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma Cells. J Biol Chem. 2015;290:15799-811 pubmed 出版商
  218. Shao H, Chung J, Lee K, Balaj L, Min C, Carter B, et al. Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nat Commun. 2015;6:6999 pubmed 出版商
  219. Rios Doria J, Sabol D, Chesebrough J, Stewart D, Xu L, Tammali R, et al. A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways. Mol Cancer Ther. 2015;14:1637-49 pubmed 出版商
  220. Bhagirath D, Zhao X, West W, Qiu F, Band H, Band V. Cell type of origin as well as genetic alterations contribute to breast cancer phenotypes. Oncotarget. 2015;6:9018-30 pubmed
  221. Zhao H, Agazie Y. Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment. BMC Cancer. 2015;15:109 pubmed 出版商
  222. Ferreira R, Law M, Jahn S, Davis B, Heldermon C, Reinhard M, et al. Novel agents that downregulate EGFR, HER2, and HER3 in parallel. Oncotarget. 2015;6:10445-59 pubmed
  223. Verfaillie A, Imrichová H, Atak Z, Dewaele M, Rambow F, Hulselmans G, et al. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nat Commun. 2015;6:6683 pubmed 出版商
  224. Hoekstra E, Kodach L, Das A, Ruela de Sousa R, Ferreira C, Hardwick J, et al. Low molecular weight protein tyrosine phosphatase (LMWPTP) upregulation mediates malignant potential in colorectal cancer. Oncotarget. 2015;6:8300-12 pubmed
  225. Wang Y, Han A, Chen E, Singh R, Chichester C, Moore R, et al. The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells. Int J Oncol. 2015;46:1924-34 pubmed 出版商
  226. Wilson F, Johannessen C, Piccioni F, Tamayo P, Kim J, Van Allen E, et al. A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell. 2015;27:397-408 pubmed 出版商
  227. Wei Z, Yu D, Bi Y, Cao Y. A disintegrin and metalloprotease 17 promotes microglial cell survival via epidermal growth factor receptor signalling following spinal cord injury. Mol Med Rep. 2015;12:63-70 pubmed 出版商
  228. Jayaprakash P, Dong H, Zou M, Bhatia A, O Brien K, Chen M, et al. Hsp90α and Hsp90β together operate a hypoxia and nutrient paucity stress-response mechanism during wound healing. J Cell Sci. 2015;128:1475-80 pubmed 出版商
  229. Sinha L, Wang Y, Yang C, Khan A, Brankov J, Liu J, et al. Quantification of the binding potential of cell-surface receptors in fresh excised specimens via dual-probe modeling of SERS nanoparticles. Sci Rep. 2015;5:8582 pubmed 出版商
  230. Haakenson J, Khokhlatchev A, Choi Y, Linton S, Zhang P, Zaki P, et al. Lysosomal degradation of CD44 mediates ceramide nanoliposome-induced anoikis and diminished extravasation in metastatic carcinoma cells. J Biol Chem. 2015;290:8632-43 pubmed 出版商
  231. Rayavarapu R, Heiden B, Pagani N, Shaw M, Shuff S, Zhang S, et al. The role of multicellular aggregation in the survival of ErbB2-positive breast cancer cells during extracellular matrix detachment. J Biol Chem. 2015;290:8722-33 pubmed 出版商
  232. Fumagalli I, Dugue D, Bibault J, Clémenson C, Vozenin M, Mondini M, et al. Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines. Onco Targets Ther. 2015;8:335-45 pubmed 出版商
  233. Dong A, Wodziak D, Lowe A. Epidermal growth factor receptor (EGFR) signaling requires a specific endoplasmic reticulum thioredoxin for the post-translational control of receptor presentation to the cell surface. J Biol Chem. 2015;290:8016-27 pubmed 出版商
  234. Greenall S, Donoghue J, van Sinderen M, Dubljevic V, Budiman S, Devlin M, et al. EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications. Oncogene. 2015;34:5277-87 pubmed 出版商
  235. Plessl K, Haider S, Fiala C, Pollheimer J, Knöfler M. Expression pattern and function of Notch2 in different subtypes of first trimester cytotrophoblast. Placenta. 2015;36:365-71 pubmed 出版商
  236. Rohatgi R, Janusis J, Leonard D, Bellvé K, Fogarty K, Baehrecke E, et al. Beclin 1 regulates growth factor receptor signaling in breast cancer. Oncogene. 2015;34:5352-62 pubmed 出版商
  237. Fillmore C, Xu C, Desai P, Berry J, Rowbotham S, Lin Y, et al. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature. 2015;520:239-42 pubmed 出版商
  238. Tian E, Stevens S, Guan Y, Springer D, Anderson S, Starost M, et al. Galnt1 is required for normal heart valve development and cardiac function. PLoS ONE. 2015;10:e0115861 pubmed 出版商
  239. Yun H, Kim H, Ga I, Oh H, Ho D, Kim J, et al. An early endosome regulator, Rab5b, is an LRRK2 kinase substrate. J Biochem. 2015;157:485-95 pubmed 出版商
  240. Yoo J, Kim T, Kong S, Lee J, Choi W, Kim K, et al. Role of Mig-6 in hepatic glucose metabolism. J Diabetes. 2016;8:86-97 pubmed 出版商
  241. Liu Z, Leng E, Gunasekaran K, Pentony M, Shen M, Howard M, et al. A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J Biol Chem. 2015;290:7535-62 pubmed 出版商
  242. Maurya S, Mishra J, Abbas S, Bandyopadhyay S. Cypermethrin Stimulates GSK3β-Dependent Aβ and p-tau Proteins and Cognitive Loss in Young Rats: Reduced HB-EGF Signaling and Downstream Neuroinflammation as Critical Regulators. Mol Neurobiol. 2016;53:968-82 pubmed 出版商
  243. Pino M, Verstraeten S. Tl(I) and Tl(III) alter the expression of EGF-dependent signals and cyclins required for pheochromocytoma (PC12) cell-cycle resumption and progression. J Appl Toxicol. 2015;35:952-69 pubmed 出版商
  244. Kumar S, Das S, Rachagani S, Kaur S, Joshi S, Johansson S, et al. NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer. Oncogene. 2015;34:4879-89 pubmed 出版商
  245. Boucrot E, Ferreira A, Almeida Souza L, Debard S, Vallis Y, Howard G, et al. Endophilin marks and controls a clathrin-independent endocytic pathway. Nature. 2015;517:460-5 pubmed 出版商
  246. Tozbikian G, Brogi E, Kadota K, Catalano J, Akram M, Patil S, et al. Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. PLoS ONE. 2014;9:e114900 pubmed 出版商
  247. Leung S, Rice P, Barton J. In vivo molecular mapping of the tumor microenvironment in an azoxymethane-treated mouse model of colon carcinogenesis. Lasers Surg Med. 2015;47:40-9 pubmed 出版商
  248. Kuo H, Huang Y, Tseng C, Chen Y, Chang Y, Shih H, et al. PML represses lung cancer metastasis by suppressing the nuclear EGFR-mediated transcriptional activation of MMP2. Cell Cycle. 2014;13:3132-42 pubmed 出版商
  249. Bollu L, Ren J, Blessing A, Katreddy R, Gao G, Xu L, et al. Involvement of de novo synthesized palmitate and mitochondrial EGFR in EGF induced mitochondrial fusion of cancer cells. Cell Cycle. 2014;13:2415-30 pubmed 出版商
  250. Smithline Z, Nikonova A, Hensley H, Cai K, Egleston B, Proia D, et al. Inhibiting heat shock protein 90 (HSP90) limits the formation of liver cysts induced by conditional deletion of Pkd1 in mice. PLoS ONE. 2014;9:e114403 pubmed 出版商
  251. Diesenberg K, Beerbaum M, Fink U, Schmieder P, Krauss M. SEPT9 negatively regulates ubiquitin-dependent downregulation of EGFR. J Cell Sci. 2015;128:397-407 pubmed 出版商
  252. Peng H, Kaplan N, Yang W, Getsios S, Lavker R. FIH-1 disrupts an LRRK1/EGFR complex to positively regulate keratinocyte migration. Am J Pathol. 2014;184:3262-71 pubmed 出版商
  253. Siggs O, Grieve A, Xu H, Bambrough P, Christova Y, Freeman M. Genetic interaction implicates iRhom2 in the regulation of EGF receptor signalling in mice. Biol Open. 2014;3:1151-7 pubmed 出版商
  254. Hong Y, Kim J, Pectasides E, Fox C, Hong S, Ma Q, et al. Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models. PLoS ONE. 2014;9:e109440 pubmed 出版商
  255. Young O, Tang Z, Niven Fairchild T, Tadesse S, Krikun G, Norwitz E, et al. Toll-like receptor-mediated responses by placental Hofbauer cells (HBCs): a potential pro-inflammatory role for fetal M2 macrophages. Am J Reprod Immunol. 2015;73:22-35 pubmed 出版商
  256. Gao X, Yu L, Moore A, Kissling G, Waalkes M, Dixon D. Cadmium and proliferation in human uterine leiomyoma cells: evidence of a role for EGFR/MAPK pathways but not classical estrogen receptor pathways. Environ Health Perspect. 2015;123:331-6 pubmed 出版商
  257. Holland W, Chinn D, Lara P, Gandara D, Mack P. Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol. 2015;141:615-26 pubmed 出版商
  258. De Santis R, Rosi A, Anastasi A, Chiapparino C, Albertoni C, Leoni B, et al. Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab. Oncotarget. 2014;5:9239-55 pubmed
  259. Hamdollah Zadeh M, Amin E, Hoareau Aveilla C, Domingo E, Symonds K, Ye X, et al. Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance. Mol Oncol. 2015;9:167-78 pubmed 出版商
  260. Czaplinska D, Turczyk L, Grudowska A, Mieszkowska M, Lipinska A, Skladanowski A, et al. Phosphorylation of RSK2 at Tyr529 by FGFR2-p38 enhances human mammary epithelial cells migration. Biochim Biophys Acta. 2014;1843:2461-70 pubmed 出版商
  261. Zhu Z, Liu Y, Li K, Liu J, Wang H, Sun B, et al. Protein tyrosine phosphatase receptor U (PTPRU) is required for glioma growth and motility. Carcinogenesis. 2014;35:1901-10 pubmed 出版商
  262. Tjin Tham Sjin R, Lee K, Walter A, Dubrovskiy A, Sheets M, Martin T, et al. In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing. Mol Cancer Ther. 2014;13:1468-79 pubmed 出版商
  263. Sakane H, Horii Y, Nogami S, Kawano Y, Kaneko Kawano T, Shirataki H. ?-Taxilin interacts with sorting nexin 4 and participates in the recycling pathway of transferrin receptor. PLoS ONE. 2014;9:e93509 pubmed 出版商
  264. Zhang L, Castanaro C, Luan B, Yang K, Fan L, Fairhurst J, et al. ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models. Mol Cancer Ther. 2014;13:1345-55 pubmed 出版商
  265. Jiang P, Nishimura T, Sakamaki Y, Itakura E, Hatta T, Natsume T, et al. The HOPS complex mediates autophagosome-lysosome fusion through interaction with syntaxin 17. Mol Biol Cell. 2014;25:1327-37 pubmed 出版商
  266. Stahlschmidt W, Robertson M, Robinson P, McCluskey A, Haucke V. Clathrin terminal domain-ligand interactions regulate sorting of mannose 6-phosphate receptors mediated by AP-1 and GGA adaptors. J Biol Chem. 2014;289:4906-18 pubmed 出版商
  267. Stratmann A, Fecher D, Wangorsch G, Göttlich C, Walles T, Walles H, et al. Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model. Mol Oncol. 2014;8:351-65 pubmed 出版商
  268. Gowing G, Shelley B, Staggenborg K, Hurley A, Avalos P, Victoroff J, et al. Glial cell line-derived neurotrophic factor-secreting human neural progenitors show long-term survival, maturation into astrocytes, and no tumor formation following transplantation into the spinal cord of immunocompromised rats. Neuroreport. 2014;25:367-72 pubmed 出版商
  269. Chen Z, Chen J, Gu Y, Hu C, Li J, Lin S, et al. Aberrantly activated AREG-EGFR signaling is required for the growth and survival of CRTC1-MAML2 fusion-positive mucoepidermoid carcinoma cells. Oncogene. 2014;33:3869-77 pubmed 出版商
  270. Brouxhon S, Kyrkanides S, Teng X, O Banion M, Clarke R, Byers S, et al. Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers. Mol Carcinog. 2014;53:893-906 pubmed 出版商
  271. Sigurdsson V, Ingthorsson S, Hilmarsdottir B, Gustafsdottir S, Franzdóttir S, Arason A, et al. Expression and functional role of sprouty-2 in breast morphogenesis. PLoS ONE. 2013;8:e60798 pubmed 出版商
  272. Fong G, Backman L, Andersson G, Scott A, Danielson P. Human tenocytes are stimulated to proliferate by acetylcholine through an EGFR signalling pathway. Cell Tissue Res. 2013;351:465-75 pubmed 出版商
  273. Yamashita M, Chattopadhyay S, Fensterl V, Saikia P, Wetzel J, Sen G. Epidermal growth factor receptor is essential for Toll-like receptor 3 signaling. Sci Signal. 2012;5:ra50 pubmed 出版商
  274. Restivo G, Nguyen B, Dziunycz P, Ristorcelli E, Ryan R, Özuysal Ö, et al. IRF6 is a mediator of Notch pro-differentiation and tumour suppressive function in keratinocytes. EMBO J. 2011;30:4571-85 pubmed 出版商
  275. Pangburn H, Kraus H, Ahnen D, Rice P. Sulindac metabolites inhibit epidermal growth factor receptor activation and expression. J Carcinog. 2005;4:16 pubmed
  276. Traxler P, Allegrini P, Brandt R, Brueggen J, Cozens R, Fabbro D, et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2004;64:4931-41 pubmed
  277. Garcia Echeverria C, Pearson M, Marti A, Meyer T, Mestan J, Zimmermann J, et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell. 2004;5:231-9 pubmed
  278. Pedersen M, Tkach V, Pedersen N, Berezin V, Poulsen H. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int J Cancer. 2004;108:643-53 pubmed